SAFETY DATA SHEET



DATE ISSUED: 8/6/2018
SDS REF. No: 4H00 SERIES

4H00 SERIES A/D WATER REDUCIBLE ENAMEL

1. PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME: 4H00 SERIES A/D WATER REDUCIBLE ENAMEL

PRODUCT CODE: 4H00 SERIES

PRODUCT USE: Industrial Waterborne Paint

MANUFACTURER 24 HR. EMERGENCY TELEPHONE NUMBER

CHEMTREC (US Transportation): (800)424-9300 CHEMTREC (International : 1(202)483-7616

Transportation)

WEB: WWW.CARDINALPAINT.COM

1329 Potrero Ave S. El Monte, CA,

626 444-9274

2. HAZARDS IDENTIFICATION

Cardinal Industrial Finishes

PICTOGRAMS



SIGNAL WORD: WARNING

HAZARD STATEMENTS:

H302+H312+H332 Harmful if swallowed, in contact or inhaled.

H319 Causes serious eye irritation.

H336 May cause drowsiness or dizziness.

H351 Suspected of causing cancer.

H373 May cause damage to organs through prolonged or repeated exposure.

PRECAUTIONARY STATEMENTS:

P264 Wash thoroughly after handling.

P280 Wear protective gloves/protective clothing/eye protection/face protection.

P312 Call a POISON CENTER or doctor/physician if you feel unwell.

P304 + P340 + P310 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Immediately call a POISON CENTER/doctor.

P337 + P313 If eye irritation persists: Get medical advice/attention.

P403 Store in a well-ventilated place.

P501 Dispose of in accordance with Local, Regional, State, Federal, and International Regulations.

S36 Wear suitable protective clothing.

S37 Wear suitable gloves.

R40 Limited evidence of a carcinogenic effect.

3. COMPOSITION/INFORMATION ON INGREDIENTS

| Chemical Name | Weight % | CAS Number |
|-----------------|----------|------------|
| Glycol Ether PM | 5% - 10% | 107-98-2 |

| Ethylene glycol mono butyl ether | 1% - 5% | 111-76-2 | |
|----------------------------------|---------|-----------|--|
| Amorphous Silica | 1% - 5% | 7631-86-9 | |

The follow substances may be present in varying quantities depending on color.

| Titanium Dioxide | 0% - 60% | 13463-67-7 | |
|------------------|----------|------------|--|
| Carbon Black | 0% - 40% | 1333-86-4 | |

4. FIRST AID MEASURES

Description of first aid measures.

EYES CONTACT: EYE CONTACT: Moderate irritation, tearing or blurred vision.

SKIN CONTACT: SKIN CONTACT: Moderate irritation possible from prolonged exposure; defatting and dermatitis.

INGESTION: INGESTION: Can cause gastrointestinal irritation, headache, dizziness, nausea and weakness.

INHALATION: INHALATION: May cause nasal irritation, headache, dizziness, nausea, weakness or vomiting. Loss of consciousness.

Most important symptoms and effects, both acute and delayed. Symptoms/injuries: Eye irritation

Symptoms/injuries after inhalation: May cause drowsiness or dizziness.

Symptoms/injuries after eye contact: Cause serious eye irritation.

Symptoms/injuries after ingestion: Ingestion may cause nausea, vomiting and diarrhea.

Indication of any immediate medical attention and special treatment needed.

If medical advise is needed, have product container or label on hand.

5. FIRE FIGHTING MEASURES

SUITABLE EXTINGUISHING MEDIA: Foam, alcohol foam, CO2, dry chemical, water fog.

FIRE FIGHTING PROCEDURE: Firefighting instructions: Use water spray or fog for cooling exposed containers. Exercise caution when fighting any chemical fire. Prevent fire-fighting water from entering the environment.

Protection during firefighting: Firefighters should wear full protective gear. Do not enter fire area without proper protective equipment, including self-contained breathing apparatus with full face piece operated in pressure demand or other positive pressure modes.

UNUSUAL FIRE AND EXPLOSION HAZARD: Fire hazard: Highly flammable/liquid or vapor.

Explosive hazard: May form flammable/explosive vapor-air mixture.

6. ACCIDENTAL RELEASE MEASURES

PERSONAL PRECAUTIONS, PROTECTIVE EQUIPMENT AND EMERGENCY PROCEDURES:

General measures: Remove ignition sources. Use special care to avoid static electric charges. No smoking.

FOR NON-EMERGENCY PERSONNEL:

For non-Emergency procedures: Evacuate unnecessary personnel.

FOR EMERGENCY RESPONDERS:

Equip cleanup crew with proper protection. Avoid breathing fume, vapors.

ENVIRONMENTAL PRECAUTIONS:

Prevent entry to sewers and public waters.

METHODS AND MATERIAL FOR CONTAINMENT AND CLEAN UP:

Collect damaged aerosols and use absorbent and/or inert material, then place in suitable container.

7. HANDLING AND STORAGE

PRECAUTIONS FOR SAFE HANDLING: Additional hazards when processed: Handle empty containers with care because residual vapors are flammable.

Precautions for safe handling: Wash hands and other exposed areas with mild soap and water before eating, drinking or smoking and when you are leaving work. Provide good ventilation in process area to prevent formation of vapor. No smoking. Use only non-sparking tools. Use outdoors or in a well ventilated area. Avoid breathing fume, vapors. Hygiene measures: Wash Skin thoroughly after handling.

CONDITIONS FOR SAFE STORAGE, INCLUDING INCOMPATIBILITIES: Storage conditions: Store in a dry, cool and well-ventilated place away from: Heat sources. Direct sunlight.

Incompatible products: Strong bases. Strong acids.

Incompatible materials: Source of ignition. Direct sunlight. Heat Sources.

8. EXPOSURE CONTROLS\PERSONAL PROTECTION

| 2-Ethylhexanoic acid(149-57-5) | | |
|---------------------------------------|-----------------------------------|----------------------|
| USA ACGIH | ACGI(TLV) RWA | 5 mg/m3, |
| Aliphatic Solvent(64742-47-8) | 7.001(124) 1.007 | 3 mg, ms, |
| USA OSHA | OSHA OEL (TLV) TWA Table Z-1 | 500 ppm, 2,000 mg/m3 |
| USA ACGIH | ACGIH (TLV) TWA | 200 mg/m3 |
| USA OSHA | OSHA OEL Table Z-1 | 5 mg/m3 |
| USA NIOSH | NIOSH REL (TWA) | 5 mg/m3 |
| USA NIOSH | NIOSH REL (ST) | 10 mg/m3 |
| Barium Sulfate(7727-43-7) | MIOSIT REE (ST) | 10 1119/1115 |
| USA ACGIH | ACGIH (TLV)TWA | 10 mg/m3 |
| USA NIOSH | NIOSH (REL) TWA | 5 mg/m3 |
| USA OSHA | OSHA (OEL) TWA | 15 mg/m3 |
| BENZENE(71-43-2) | OSTIA (OLL) TWA | 13 mg/ms |
| USA ACGIH | ACGIH TWA | 0.5 ppm |
| USA ACGIH | ACGIN TWA | 2.5 ppm |
| USA OSHA | OSHA TWA (Table Z-1-A) | |
| USA OSHA | | 1 ppm |
| USA OSHA | OSHA CIEL (Table Z-1-A) OSHA STEL | 5 ppm |
| | | 5 ppm |
| USA OSHA USA OSHA | OSHA CARC PEL | 1 ppm |
| | OSHA CARC STEL | 5 ppm |
| Butyl Alcohol(71-36-3) | A COTH (TIM) THA | |
| USA ACGIH | ACGIH (TLV) TWA | 20 ppm |
| USA OSHA | OSHA (OEL) TWA Table Z-1 | 100 ppm, 300 mg/m3 |
| USA NIOSH | NIOSH (REL) C | 50 ppm, 150 mg/m3 |
| Carbon Black(1333-86-4) | | |
| USA ACGIH | ACGIH TLV (mg/m3) | 3.0 mg/m3 |
| USA OSHA | OSHA PEL (mg/m3) | 3.5 mg/m3 |
| Ethylene glycol mono butyl ether(111- | | 1 |
| USA ACGIH | ACGIH TWA (ppm) | 20 ppm |
| USA NIOSH | NIOSH REL (ppm) | 5 ppm |
| USA OSHA | OSHA TABLE Z-1 TWA (mg/m3) | 50 ppm, 240 mg/m3 |
| USA OSHA | OSHA PO TWA (ppm) | 25 ppm |
| Glycol Ether PM(107-98-2) | | |
| USA ACGIH | ACGIH (TLV) (TWA) | 50 ppm |
| USA ACGIH | ACGIH (TLV) STEL | 100 ppm |
| USA NIOSH | NIOSH (TWA) | 100 ppm, 360 mg/m3 |
| USA NIOSH | NIOSH (TLV) ST | 150 ppm, 540 mg/m3 |
| Meta-Xylene(108-38-3) | | |
| USA ACGIH | ACGIH TWA (8 h) | 100 ppm, 434 mg/m3 |
| USA ACGIH | ACGIH STEL TLV (15 m) | 150 ppm, 651 mg/m3 |
| USA OSHA | OSHA TWA (8 h) | 100 ppm, 435 mg/m3 |
| Methyl Ethyl Ketoxime(96-29-7) | | |
| USA WEEL | (WEEL) TWA | 10 ppm |
| Phenylethane(100-41-4) | | |
| USA ACGIH | ACGIH TWA | 20 ppm |
| USA ACGIH | ACGIH STEL | 125 ppm |
| USA NIOSH | NIOSH REL | 100 ppm, 435 mg/m3 |
| USA NIOSH | NIOSH REL (ST) | 125 ppm, 545 mg/m3 |
| USA OSHA | OSHA TWA (Table Z-1) | 100 ppm, 435 mg/m3 |
| USA OSHA | OSHA STEL | 125 ppm, 545 mg/m3 |
| Red Iron Oxide(1309-37-1) | | |
| Occupational Exposure Limits | No Data Available | |
| | • | |

| Appropriate Engineering Controls | Use only with adequate ventilation. If | |
|---|---|---|
| Appropriate Engineering controls | user operations generate dust, | |
| | fumes, gas, vapor or mist, use | |
| | process enclosures, local exhaust | |
| | ventilations or other engineering | |
| | controls to keep worker exposure to | |
| | airborne containments below any | |
| | recommended or statutory limits. | |
| Darsonal Protections | | |
| Personal Protections | Hygiene Measures - Wash hands, | |
| | forearms, and face thoroughly after | |
| | handling chemical products, before | |
| | eating, smoking and using the lab | |
| | and at the end of the working period. | |
| | Appropriate techniques should be | |
| | used to remove potentially | |
| | contaminated clothing. Wash | |
| | contaminated clothing before reusing. | |
| | Ensure that eyewash stations and | |
| | safety showers are close to the | |
| | workstation location. | |
| Respiratory Protections | The following respirator is | |
| | recommended if airborne | |
| | concentrations exceed the | |
| | appropriate standard/guideline. | |
| | NIOSH approved, air-purifying | |
| | particulate respirator with N-95 | |
| | filters. | |
| Skin Protections | Wear suitable protective clothing and | |
| | gloves. Suitable protective footwear. | |
| | | |
| Eye/Face Protection | If contact with product is possible, | |
| | wear safety glasses with side shields. | |
| Medical Surveillance | | |
| Medical Surveillance Titanium Dioxide(13463-67-7) | wear safety glasses with side shields. | |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) | wear safety glasses with side shields. No Data Available OSHA TWA | 15 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) | wear safety glasses with side shields. No Data Available | 15 mg/m3 10 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) | wear safety glasses with side shields. No Data Available OSHA TWA | |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV | wear safety glasses with side shields. No Data Available OSHA TWA | |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA ACGIH TWA | 10 mg/m3 20 ppm |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA ACGIH TWA NIOSH REL TWA | 20 ppm 100 ppm, 375 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) | 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) | 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) | 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) | 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA Triethylamine(121-44-8) | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) | 10 mg/m3 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA Triethylamine(121-44-8) USA ACGIH | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) ACGIH (TLV)TWA | 10 mg/m3 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 1 ppm |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA Triethylamine(121-44-8) USA ACGIH USA ACGIH | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) ACGIH (TLV)TWA ACGIH (TLV) STEL | 10 mg/m3 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 1 ppm 3 ppm |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA USA OSHA Triethylamine(121-44-8) USA ACGIH USA ACGIH USA ACGIH USA OSHA | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) ACGIH (TLV)TWA | 10 mg/m3 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 1 ppm |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA USA OSHA Triethylamine(121-44-8) USA ACGIH USA ACGIH USA ACGIH USA OSHA VM&P Naphtha(64742-89-8) | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) ACGIH (TLV)TWA ACGIH (TLV) STEL OSHA (OEL) TWA Table Z-1 | 10 mg/m3 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 1 ppm 3 ppm 25 ppm, 100 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA Triethylamine(121-44-8) USA ACGIH USA ACGIH USA ACGIH USA OSHA Triethylamine(121-44-8) USA OSHA | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) ACGIH (TLV)TWA ACGIH (TLV) STEL OSHA (OEL) TWA Table Z-1 | 10 mg/m3 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 1 ppm 3 ppm 25 ppm, 100 mg/m3 400 ppm, 1,600 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA Triethylamine(121-44-8) USA ACGIH USA ACGIH USA ACGIH USA OSHA Triethylamine(121-44-8) USA ACGIH USA OSHA USA OSHA USA OSHA VM&P Naphtha(64742-89-8) USA OSHA USA OSHA | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) ACGIH (TLV)TWA ACGIH (TLV) STEL OSHA (OEL) TWA Table Z-1 | 10 mg/m3 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 1 ppm 3 ppm 25 ppm, 100 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA Triethylamine(121-44-8) USA ACGIH USA ACGIH USA ACGIH USA OSHA Triethylamine(121-44-8) USA OSHA TYPE SA ACGIH USA OSHA VM&P Naphtha(64742-89-8) USA OSHA VM&P Naphtha(64742-89-8) USA OSHA Xylene(1330-20-7) | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) ACGIH (TLV)TWA ACGIH (TLV) STEL OSHA (OEL) TWA Table Z-1 OSHA TWA (Table PO) OSHA TWA (Table Z-1) | 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 1 ppm 3 ppm 25 ppm, 100 mg/m3 400 ppm, 1,600 mg/m3 500 ppm, 2,000 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA Triethylamine(121-44-8) USA ACGIH USA ACGIH USA OSHA Triethylamine(121-44-8) USA ACGIH USA OSHA VM&P Naphtha(64742-89-8) USA OSHA VM&P Naphtha(64742-89-8) USA OSHA Xylene(1330-20-7) USA ACGIH | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) ACGIH (TLV)TWA ACGIH (TLV) STEL OSHA (OEL) TWA Table Z-1 OSHA TWA (Table PO) OSHA TWA (Table PO) OSHA TWA (Table Z-1) | 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 1 ppm 3 ppm 25 ppm, 100 mg/m3 400 ppm, 1,600 mg/m3 500 ppm, 2,000 mg/m3 |
| Medical Surveillance Titanium Dioxide(13463-67-7) PEL (Permissible Exposure Limit) TLV Toluene(108-88-3) USA ACGIH USA NIOSH USA NIOSH USA OSHA USA OSHA Triethylamine(121-44-8) USA ACGIH USA ACGIH USA ACGIH USA OSHA Triethylamine(121-44-8) USA OSHA TYPE SA ACGIH USA OSHA VM&P Naphtha(64742-89-8) USA OSHA VM&P Naphtha(64742-89-8) USA OSHA Xylene(1330-20-7) | wear safety glasses with side shields. No Data Available OSHA TWA ACGIH TWA NIOSH REL TWA NIOSH REL (ST) OSHA TWA (Table Z-2) OSHA TWA (PO) OSHA STEL (PO) ACGIH (TLV)TWA ACGIH (TLV) STEL OSHA (OEL) TWA Table Z-1 OSHA TWA (Table PO) OSHA TWA (Table Z-1) | 20 ppm 100 ppm, 375 mg/m3 150 ppm, 560 mg/m3 200 ppm 100 ppm, 375 ppm 150 ppm, 560 mg/m3 1 ppm 3 ppm 25 ppm, 100 mg/m3 400 ppm, 1,600 mg/m3 500 ppm, 2,000 mg/m3 |

PERSONAL PROTECTIVE EQUIPMENT

RESPIRATORY PROTECTION: If TLV of the product or any component is exceeded, a NIOSH approved Air Supplied Respirator is advised in absence of environmental control. OSHA Regulations also permit other NIOSH Respirators under specified conditions. (See your Safety Equipment Supplier) Engineering or administrative controls should be implemented to reduce exposure.

HAND PROTECTION REMARKS : The suitability for a specific workplace should be discussed with the producers of the protective gloves.

EYES PROTECTION: Do not get in eyes. Solvent resistant safety eyewear with splash guards or side shields is recommended.

SKIN AND BODY PROTECTION: Prevent repeated or prolonged skin contact with GB Protective Handcream, wear impervious clothing and chemical resistant boots.

WORK HYGIENIC PRACTICES: Remove and wash soiled clothing before reuse. Wash hands with soap and water after handling paint, before eating, using the rest room or smoking.

9. PHYSICAL AND CHEMICAL PROPERTIES

| Physical state | : | Liquid |
|---------------------------|----------|---|
| Color | : | Various colors depending on the pigmentation. |
| Odor | : | Characteristic. Sweet. Mint like. |
| Odor threshold | : | No data available. |
| Ph | : | N/A - See Technical Data Sheet |
| Evaporation rate | : | Slower Than Ether |
| Melting point | : | -94.7 C (-138.46 F) |
| Freezing point | : | No data available. |
| Boiling point | : | 246.0 deg F TO 334.0 deg F |
| Flash point | : | Above 212 deg F |
| Lower explosion limit | : | No data available. |
| Upper explosion limit | : | No data available. |
| Vapor pressure | : | 185 mm Hg |
| Vapor density | : | Heavier than air |
| Relative density | : | No data available. |
| Density | : | 10.0242 |
| Solubility | : | No data available. |
| Partion coefficient: n- | : | No data available. |
| octanol/water | | |
| Autoignition temperature | : | No data available. |
| Decomposition temperature | <u>:</u> | No data available. |

10. STABILITY AND REACTIVITY

REACTIVITY: No dangerous reaction known under conditions of normal use.

CHEMICAL STABILITY: Stable.

CONDITIONS TO AVOID: Extremely high temperatures, poor ventilation and excessive aging.

INCOMPATIBLE MATERIALS: Avoid contact with strong oxidizing agents.

HAZARDOUS DECOMPOSITION PRODUCTS: Hazardous decomposition may produce carbon dioxide and/or carbon monoxide.

11. TOXICOLOGICAL INFORMATION

| 1,10-Phenanthroline(66-71-7) | | |
|------------------------------|--|--|
| LD50 Oral - Rat - | 132 mg/kg | |
| Acute toxicity | | |
| 2-Ethylhexanoic acid(14) | 9-57-5) | |
| LD50 Oral - Rat - | 3,000 mg/kg, Oral, Rat | |
| Acute toxicity | | |
| Inhalation | No data available. | |
| LD50 Dermal - Rabbit | 1,142 mg/kg, Dermal, Rabbit | |
| Skin | No data available. | |
| corrosion/irritation | | |
| Serious eye | Eyes - rabbit Result: Severe eye irritation | |
| damage/eye irritation | | |
| Respiratory or skin | No data available. | |
| sensitization | | |
| Germ cell mutagenicity | Human lymphocyte Sister chromatic exchange | |
| Carcinogenicity | IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH. NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA. | |
| Reproductive toxicity | Suspected human reproductive toxicant no data available no data available Developmental Toxicity - rat - Oral Effects on Embryo or Fetus: Fetotoxicity (except death, e.g., stunted | |

| | fetus). Developmental Toxicity - rat - Oral Specific Developmental Abnormalities: Musculoskeletal system. Specific Developmental Abnormalities: Cardiovascular (circulatory) system. Specific Developmental Abnormalities: Urogenital system. |
|---|--|
| Specific target organ toxicity - single | No data available. |
| exposure | |
| Specific target organ | No data available. |
| toxicity - repeated | |
| exposure | |
| Aspiration hazard | No data available. |
| Additional Information | RTECS: MO7700000 To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Stomach - Irregularities - Based on Human Evidence Stomach - Irregularities - Based on Human Evidence. |
| Aliphatic Solvent(64742 | -47-8) |
| Acute toxicity | No data available. |
| Acute Inhalation toxicity | No data available. |
| Acute Dermal toxicity | No data available. |
| Skin corrosion/irritation | Skin - Rabbit Result: No skin irritation - 4 h |
| Serious eye damage/eye irritation | Eyes - Rabbit Result: No eye irritation |
| Respiratory or skin sensitization | Draize Test - Guinea pig Result: Does not cause skin sensitization. |
| Germ cell mutagenicity | Reverse mutation assay S. typhimurium Result: negative |
| Carcinogenicity | IARC: 3 - Group 3: Not classifiable as to its carcinogenicity to humans (Distillates (petroleum), hydrotrated light, kerosene - unspecified) NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA. |
| Reproductive toxicity | No data available. |
| Specific target organ | No data available. |
| toxicity - single exposure | |
| Specific target organ | No data available. |
| toxicity - repeated exposure | |
| Aspiration hazard | No data available. |
| Additional Information | RTECS: Not available Prolonged or repeated exposure to skin causes defatting and dermatitis., To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. |
| Barium Sulfate(7727-43 | |
| LD50 Oral - Rat - Acute toxicity | >15,000 mg/kg |
| Irritation/corrosion | Product not irritating to eyes or skin. |
| Sensitsation | No sinsibilisation known. |
| Chronic Toxicity | No toxic effects known. |
| BENZENE(71-43-2) | |
| LD50 Oral | > 2,000 mg/kg Species: rat Sex: female |
| LC50 Dermal | 44.5 mg/l Exposure time: 4 h Species: rat Sex: Not Specified Test atmosphere: vapor |
| LD50 | > 8,260 mg/kg Species: rabbit |
| Skin irritation | May cause skin irritation in susceptible persons. |
| Eye irritation | May cause irreversible eye damage. |
| Sensitization Pencated dose toxicity | Did not cause sensitization on laboratory animals. |
| Repeated dose toxicity | Species: rat, female Sex: female. Application Route: oral gavage Dose: 0, 25, 50, 100 mg/kg Exposure time: 103 wk Number of exposures: 5 d/wk NOEL: < 25 mg/kg Lowest observable effect level: 25 mg/kg Species: rat, male Sex: male Application Route: oral gavage Dose: 0, 50, 100, 200 mg/kg Exposure time: 103 wk Number of exposures: 5 d/wk NOEL: < 50 mg/kg Lowest observable effect level: 50 mg/kg Species: mouse Application Route: oral gavage Dose: 0, 25, 50,100 mg/kg Exposure time: 103 wk NOEL: < 25 mg/kg |
| Carcinogenicity | Species: rat Sex: female Dose: 0, 25, 50, 250 mg/kg Exposure time: 103 wks Number of exposures: daily, 5 days/week Test substance: yes Remarks: zymbal gland carcinomas, squamous cell papillomas Species: rat Sex: male Dose: 0, 50, 100, 200 mg/kg Exposure time: 103 wks Number of exposures: daily, 5 days/week Test substance: yes Remarks: zymbal gland carcinomas, squamous cell papillomas Species: mouse Sex: male and female Dose: 25, 50, 100 mg/kg Exposure time: 103 wks Number of exposures: daily, 5 days/week Test substance: yes Remarks: Clear evidence of multiple organ carcinogenicity. |
| Aspiration toxicity | May be fatal if swallowed and enters airways. Substances known to cause human aspiration toxicity hazards or to be regarded as if they cause human aspiration toxicity hazard. |
| | |

| | Carcinogenicity: Human carcinogen. Mutagenicity: In vivo tests showed mutagenic effects Teratogenicity: Did not show teratogenic effects in animal experiments. Reproductive toxicity: |
|--|---|
| | Animal testing did not show any effects on fertility. |
| Further information Butyl Alcohol(71-36-3) | Chronic Health Hazard. Solvents may degrease the skin. |
| LD50 Oral - Rat - | 790 mg/kg, Liver:Fatty liver degeneration. Kidney, Ureter, Bladder:Other changes. |
| Acute Toxicity | Blood:Other changes. |
| LC50 Inhalation Rat | 8,000 ppm, Rat, 4 h |
| LD50 Dermal - Rabbit | 3,400 mg/kg |
| Skin | Rabbit Result: Skin irritation - 24 h |
| corrosion/irritation | |
| Serious Eye Damage and Irritation | Serious eye damage,eye irritation Eyes - Rabbit Result: Blindness (OECD Test Guideline 405) |
| Respiratory or skin sensitsation | No data available |
| Germ cell mutagenicity | No data available |
| Carcinogenicity | IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH. NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA. |
| Reproductively toxicity | No data available |
| Specific target organ toxicity - single exposure | May cause respiratory irritation. May cause drowsiness or dizziness |
| Specific target organ toxicity - repeated | No data available |
| exposure | No data quallable |
| Aspiration hazard Additional Information | No data available |
| | RTECS: EO1400000 drying, cracking of the skin, Skin irritation To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Stomach - Irregularities - Based on Human Evidence Stomach - Irregularities - Based on Human Evidence |
| Carbon Black(1333-86-4 | |
| LD50 (Rat) | >8000 mg/kg |
| Carcinogenicity | GHS- Not a hazardous substance or preparation according to the Global Harmonized System |
| Classification IARC | (GHS). IARC In 1995 IARC concluded, "There is inadequate evidence in humans for the carcinogenicity of carbon black." Based on rat inhalation studies IARC concluded that there is, "sufficient evidence in experimental animals for the carcinogenicity of carbon black," IARC's |
| | overall evaluation was that, "Carbon black is possibly carcinogenic to humans (Group 2B)". This conclusion was based on IARC's guidelines, which require such a classification if one species exhibits carcinogenicity in two or more studies. IARC performed another review in 2006, and again classified carbon black as possibly carcinogenic to humans (Group 2B). In its 1987 review IARC concluded, "There is sufficient evidence in experimental animals for the carcinogenicity of carbon black extracts." Carbon black extracts are classified as, possibly carcinogenic to humans (Group 2B). |
| NTP | overall evaluation was that, "Carbon black is possibly carcinogenic to humans (Group 2B)". This conclusion was based on IARC's guidelines, which require such a classification if one species exhibits carcinogenicity in two or more studies. IARC performed another review in 2006, and again classified carbon black as possibly carcinogenic to humans (Group 2B). In its 1987 review IARC concluded, "There is sufficient evidence in experimental animals for the carcinogenicity of carbon black extracts." Carbon black extracts are classified as, possibly |
| NTP | overall evaluation was that, "Carbon black is possibly carcinogenic to humans (Group 2B)". This conclusion was based on IARC's guidelines, which require such a classification if one species exhibits carcinogenicity in two or more studies. IARC performed another review in 2006, and again classified carbon black as possibly carcinogenic to humans (Group 2B). In its 1987 review IARC concluded, "There is sufficient evidence in experimental animals for the carcinogenicity of carbon black extracts." Carbon black extracts are classified as, possibly carcinogenic to humans (Group 2B). NTP Carbon black is not designated a carcinogen by the U.S. National Toxicology Program (NTP), the U.S. Occupational Safety and Health Administration (OSHA) or the European Union (EU). ACGIH The American Conference of Governmental Industrial Hygienists classifies carbon black |
| | overall evaluation was that, "Carbon black is possibly carcinogenic to humans (Group 2B)". This conclusion was based on IARC's guidelines, which require such a classification if one species exhibits carcinogenicity in two or more studies. IARC performed another review in 2006, and again classified carbon black as possibly carcinogenic to humans (Group 2B). In its 1987 review IARC concluded, "There is sufficient evidence in experimental animals for the carcinogenicity of carbon black extracts." Carbon black extracts are classified as, possibly carcinogenic to humans (Group 2B). NTP Carbon black is not designated a carcinogen by the U.S. National Toxicology Program (NTP), the U.S. Occupational Safety and Health Administration (OSHA) or the European Union (EU). ACGIH The American Conference of Governmental Industrial Hygienists classifies carbon black as A4, Not Classifiable as a Human Carcinogen. NIOSH The U.S. National Institute of Occupational Safety and Health (NIOSH) 1978 criteria document on carbon black recommends that only carbon blacks with PAH contaminant levels greater than 0.1% require the measurement of PAHs in air. As some PAHs are possible human carcinogens, NIOSH recommends an exposure limit of 0.1 mg/m3 for PAHs in air, |
| ACGIH | overall evaluation was that, "Carbon black is possibly carcinogenic to humans (Group 2B)". This conclusion was based on IARC's guidelines, which require such a classification if one species exhibits carcinogenicity in two or more studies. IARC performed another review in 2006, and again classified carbon black as possibly carcinogenic to humans (Group 2B). In its 1987 review IARC concluded, "There is sufficient evidence in experimental animals for the carcinogenicity of carbon black extracts." Carbon black extracts are classified as, possibly carcinogenic to humans (Group 2B). NTP Carbon black is not designated a carcinogen by the U.S. National Toxicology Program (NTP), the U.S. Occupational Safety and Health Administration (OSHA) or the European Union (EU). ACGIH The American Conference of Governmental Industrial Hygienists classifies carbon black as A4, Not Classifiable as a Human Carcinogen. NIOSH The U.S. National Institute of Occupational Safety and Health (NIOSH) 1978 criteria document on carbon black recommends that only carbon blacks with PAH contaminant levels greater than 0.1% require the measurement of PAHs in air. As some PAHs are possible |
| ACGIH NIOSH STOT- single exposure | overall evaluation was that, "Carbon black is possibly carcinogenic to humans (Group 2B)". This conclusion was based on IARC's guidelines, which require such a classification if one species exhibits carcinogenicity in two or more studies. IARC performed another review in 2006, and again classified carbon black as possibly carcinogenic to humans (Group 2B). In its 1987 review IARC concluded, "There is sufficient evidence in experimental animals for the carcinogenicity of carbon black extracts." Carbon black extracts are classified as, possibly carcinogenic to humans (Group 2B). NTP Carbon black is not designated a carcinogen by the U.S. National Toxicology Program (NTP), the U.S. Occupational Safety and Health Administration (OSHA) or the European Union (EU). ACGIH The American Conference of Governmental Industrial Hygienists classifies carbon black as A4, Not Classifiable as a Human Carcinogen. NIOSH The U.S. National Institute of Occupational Safety and Health (NIOSH) 1978 criteria document on carbon black recommends that only carbon blacks with PAH contaminant levels greater than 0.1% require the measurement of PAHs in air. As some PAHs are possible human carcinogens, NIOSH recommends an exposure limit of 0.1 mg/m3 for PAHs in air, measured as the cyclohexane-extractable fraction. Inhalation studies with the rat showed lung effects (see Section 11.2 and 11.3), these effects are believed to be the effects of "lung overload" 1 and these effects are believed to be specific to the species. In addition, the European CLP Regulation states that no classification is necessary if the mechanism is not relevant to humans. 4) Also, the CLP Guidance on classification and labeling states that the "lung overload" mechanism is not relevant to |
| ACGIH NIOSH STOT- single exposure | overall evaluation was that, "Carbon black is possibly carcinogenic to humans (Group 2B)". This conclusion was based on IARC's guidelines, which require such a classification if one species exhibits carcinogenicity in two or more studies. IARC performed another review in 2006, and again classified carbon black as possibly carcinogenic to humans (Group 2B). In its 1987 review IARC concluded, "There is sufficient evidence in experimental animals for the carcinogenicity of carbon black extracts." Carbon black extracts are classified as, possibly carcinogenic to humans (Group 2B). NTP Carbon black is not designated a carcinogen by the U.S. National Toxicology Program (NTP), the U.S. Occupational Safety and Health Administration (OSHA) or the European Union (EU). ACGIH The American Conference of Governmental Industrial Hygienists classifies carbon black as A4, Not Classifiable as a Human Carcinogen. NIOSH The U.S. National Institute of Occupational Safety and Health (NIOSH) 1978 criteria document on carbon black recommends that only carbon blacks with PAH contaminant levels greater than 0.1% require the measurement of PAHs in air. As some PAHs are possible human carcinogens, NIOSH recommends an exposure limit of 0.1 mg/m3 for PAHs in air, measured as the cyclohexane-extractable fraction. Inhalation studies with the rat showed lung effects (see Section 11.2 and 11.3), these effects are believed to be the effects of "lung overload" 1 and these effects are believed to be specific to the species. In addition, the European CLP Regulation states that no classification is necessary if the mechanism is not relevant to humans. 4) Also, the CLP Guidance on classification and labeling states that the "lung overload" mechanism is not relevant to humans. 4) Therefore, no STOT, Repeated Exposure classification is made |
| ACGIH NIOSH STOT- single exposure STOT- repeated exposure | overall evaluation was that, "Carbon black is possibly carcinogenic to humans (Group 2B)". This conclusion was based on IARC's guidelines, which require such a classification if one species exhibits carcinogenicity in two or more studies. IARC performed another review in 2006, and again classified carbon black as possibly carcinogenic to humans (Group 2B). In its 1987 review IARC concluded, "There is sufficient evidence in experimental animals for the carcinogenicity of carbon black extracts." Carbon black extracts are classified as, possibly carcinogenic to humans (Group 2B). NTP Carbon black is not designated a carcinogen by the U.S. National Toxicology Program (NTP), the U.S. Occupational Safety and Health Administration (OSHA) or the European Union (EU). ACGIH The American Conference of Governmental Industrial Hygienists classifies carbon black as A4, Not Classifiable as a Human Carcinogen. NIOSH The U.S. National Institute of Occupational Safety and Health (NIOSH) 1978 criteria document on carbon black recommends that only carbon blacks with PAH contaminant levels greater than 0.1% require the measurement of PAHs in air. As some PAHs are possible human carcinogens, NIOSH recommends an exposure limit of 0.1 mg/m3 for PAHs in air, measured as the cyclohexane-extractable fraction. Inhalation studies with the rat showed lung effects (see Section 11.2 and 11.3), these effects are believed to be the effects of "lung overload" 1 and these effects are believed to be specific to the species. In addition, the European CLP Regulation states that no classification is necessary if the mechanism is not relevant to humans. 4) Also, the CLP Guidance on classification and labeling states that the "lung overload" mechanism is not relevant to humans. 4) Therefore, no STOT, Repeated exposure classification is made. |

| | observation is believed to be rat specific and a consequence of "lung overload" which led to chronic inflammation and release of genotoxic oxygen species. This mechanism is considered to be a secondary genotoxic effect and thus, carbon black itself would not be considered to be mutagenic. Carbon black is not suitable to be tested in bacterial (Ames test) and other in vitro systems because of its insolubility in aqueous solutions. When tested, however, results for carbon black showed no mutagenic effects. Organic solvent extracts of carbon black can, however, contain traces of polycyclic aromatic hydrocarbons (PAHs). A study to examine the bioavailability of these PAHs showed that PAHs are very tightly bound to carbon black and not bioavailable. |
|---------------------------------------|--|
| Reproductive and Teratogenic Effects | No experimental studies on effects of carbon black on fertility and reproduction have been located. However, based on toxicokinetic data, carbon black is deposited in the lungs and based on its specific physicochemical properties (insolubility, low absorption potential), it is not likely to distribute in the body to reach reproductive organs, embryo and/or foetus under in vivo conditions. Therefore, no adverse effects of carbon black to fertility/reproduction or to foetal development are expected. No effects have been reported in long-term animal studies. |
| Human Epidemiology | Results of epidemiological studies of carbon black production workers suggest that cumulative exposure to carbon black may result in small decrements in lung function, as measured by FEV1. A recent U.S. respiratory morbidity study suggested a 27 mL decline in FEV1 from a 1 mg/m3 (inhalable fraction) exposure over a 40-year period. An older European investigation suggested an exposure to 1 mg/m3 (inhalable fraction) of carbon black over a 40-year working-lifetime will result in a 48 mL decline in FEV1. In contrast, normal age related decline over a similar period of time would be approximately 1200 ml. The relationship between symptoms and exposure to carbon black is less clear. In the U.S. study, 9% of the highest exposure group (in contrast to 5% of the unexposed group) reported symptoms consistent with chronic bronchitis. In the European study, methodological limitations in the administration of the questionnaire limit the drawing of definitive conclusions about symptoms. |
| Human Epidemiology - cont. | This study, however, indicated a link between carbon black and small opacities on chest films, with negligible effects on lung function. A study on carbon black production workers in the UK 10) found an increased risk of lung cancer in two of the five plants studied; however, the increase was not related to the dose of carbon black. Thus, the authors did not consider the increased risk in lung cancer to be due to carbon black exposure. A German study of carbon black workers at one plant 11-14) found a similar increase in lung cancer risk but, like the 2001 UK study 10), found no association with carbon black exposure. In contrast, a large US study 15) of 18 plants showed a reduction in lung cancer risk in carbon black production workers. Based upon these studies, the February 2006 Working Group at IARC concluded that the human evidence for carcinogenicity was inadequate 1). |
| Human Epidemiology - cont | Since this IARC evaluation of carbon black, Sorahan and Harrington 16) re-analyzed the UK study data using an alternative exposure hypothesis and found a positive association with carbon black exposure in two of the five plants. The same exposure hypothesis was applied by Morfeld and McCunney 17-18) to the German cohort; in contrast, they found no association between carbon black exposure and lung cancer risk and, thus, no support for the alternative exposure hypothesis used by Sorahan and Harrington 16). |
| Human Epidemiology - cont. | Morfeld and McCunney 19) applied a Bayesian approach to unravel the role of uncontrolled confounders and identified smoking and prior exposure to occupational carcinogens received before being hired in the carbon black industry as main causes of the observed lung cancer excess risk. Overall, as a result of these detailed investigations, no causative link between carbon black exposure and cancer risk in humans has been demonstrated. This view is consistent with the IARC evaluation in 2006. Several epidemiological and clinical studies of workers in the carbon black production industries show no evidence of clinically significant adverse health effects due to occupational exposure to carbon black. No dose response relationship was observed in workers exposed to carbon black. |
| Ethylene glycol mono bu | Acute toxicity estimate: 500 mg/kg; Method: Expert judgment.; Assessment: the |
| LC50 (rat) inhalation | component/mixture is moderately toxic after single ingestion. Acute inhalation toxicity: 500 ppm, Exposure time: 4 h; Assessment: the component/mixture |
| LD50 (rat) dermal | is moderately toxic after short term inhalation. Acute toxicity estimate: 1,1000 mg/kg; Method: Expert judgment; Assessment: the |
| . , , | component/mixture is moderately toxic after single contact with skin. |
| Skin corrosion/irritation | Remarks: Moderate skin irritation in susceptible persons., Species rabbit, Exposure time 24 h, Result: Mild skin irritation |
| Serious eye damage/ eye irritation | Species rabbit, Exposure time 24 h, Result: Irritating to eyes. |
| Respiratory or skin sensitsation | Test Type: Maximization test, Species guinea pig, Result: Did not cause sensitsation on laboratory animals. |
| Germ cell mutagenicity | Genotoxicity in vitro: Test Type: Mammalian cell gene mutation assay; Test species: Chinese hamster (CHO), Metabolic activation: with and without metabolic activation. Result: negative., Genotoxicity in vivo: Test Type: In vivo micronucleus test., Test species:: mouse (male), application Route: Intraperitoneal, Result: negative., Germ cell mutagenicity Assessment: Tests on bacterial or mammalian did not show mutagenic effects. |

| Carcinogenicity | Species mouse, Application Route: Inhalation, Exposure time 2 yr, Activity duration: 6 h, Frequency of Treatment: 5 days/week, NAOEL: 125 ppm Result: Limited evidence of carcinogenic effects with no relevance to humans., Carcinogenicity-Assement: Not evidence of carcinogenicity in animal studies |
|--|---|
| Reproductive toxicity | Effects on fertility: Test Type: Two-generation study Species: mouse Application Route: oral Fertility: NOAEL: 720 mg/kg body weight Symptoms: Reduced fertility Result: Reduced fertility at maternally toxic doses Effects on fetal development: Test Type: Embryo-fetal development Species: rat Application Route: Inhalation Duration of Single Treatment: 10 d Frequency of Treatment: 6 hr/day Developmental Toxicity: Lowest observed adverse effect level: 100 ppm Result: Developmental toxicity occurred at maternal toxicity dose levels Reproductive toxicity - Assessment: No evidence of adverse effects on sexual function and fertility, and on development, based on animal experiments |
| STOT - single exposure | No data available. |
| STOT - repeated exposure | No data available. |
| Aspiration toxicity | Remarks: No data available. |
| Further information | Product Remarks: Symptoms of overexposure may be headache, dizziness, tiredness, nausea and vomiting., |
| Repeated dose toxicity | Species: rat NOAEL: 30, Application Route: Inhalation Exposure time: 14 wk Number of exposures: 6 h/d, 5 d/wk. |
| Glycol Ether PM(107-98- | 2) |
| LD50 Oral - Mouse - Acute Toxicity | 11,700 mg/kg, Behavioral:Convulsions or effect on seizure threshold. Behavioral: Ataxia. Lungs, Thorax, or Respiration:Dyspnea. |
| LC50 Inhalation - Rat - Inhalation | 10000 ppm, - Rat - 5 h |
| LD50 Dermal - Rabbit - Dermal | 13,000 mg/kg, Rabbit |
| Skin corrosion/irritation | No data available. |
| Serious eye damage/eye irritation | Eyes - Rabbit Result: Mild eye irritation - 24 h Respiratory or skin sensitization |
| Germ cell mutagenicity | No data available |
| Carcinogenicity | IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA. |
| Reproductive toxicity | No data available. |
| Specific target organ toxicity - single exposure | May cause drowsiness or dizziness. |
| Specific target organ toxicity - repeated exposure | No data available. |
| Aspiration hazard | No data available. |
| Additional Information | RTECS: UB7700000 To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Stomach - Irregularities - Based on Human Evidence Stomach - Irregularities - Based on Human Evidence |
| Additional Information | RTECS: UB7700000 To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Stomach - Irregularities - Based on Human Evidence Stomach - Irregularities - Based on Human Evidence. |
| Meta-Xylene(108-38-3) | |
| LD50 Oral (Rat, Male) | 6,602 mg/kg (OECD Test Guideline 401) |
| LC50 Inhalation (Rat, Male) | 6700 ppm, 4 h - (Directive 67/548/EEC, Annex V, B.2.) |
| LD50 Dermal (Rabbit, Male) | 12,126 mg/kg Remarks: Classified according to Regulation (EU) 1272/2008, Annex VI (Table 3.1/3.2). No data available. |
| Skin corrosion/irritation | Skin - Rabbit Result: Skin irritation - 24 h |
| Serious eye damage/eye irritation | Eyes - Rabbit Result: Severe eye irritation - 24 h |
| Respiratory or skin sensitization | Mouse Result: Does not cause skin sensitization. (OECD Test Guideline 429) |
| Germ cell mutagenicity | No data available. |
| Carcinogenicity | This product is or contains a component that is not classifiable as to its carcinogenicity based on its IARC, ACGIH, NTP, or EPA classification. IARC: 3 - Group 3: Not classifiable as to its carcinogenicity to humans (m-Xylene) NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. OSHA: No component of this product presents at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA. |

| Reproductive toxicity Specific target organ | Overexposure may cause reproductive disorder(s) based on tests with laboratory animals. Inhalation - May cause respiratory irritation. |
|--|---|
| toxicity - single exposure | |
| Specific target organ | No data available. |
| toxicity - repeated | |
| exposure | Mary by Catal Standard and antenna simons |
| Aspiration hazard Additional Information | May be fatal if swallowed and enters airways. RTECS: ZE2275000 Liver injury may occur., Kidney injury may occur., Blood disorders, |
| Additional Information | burning sensation, Cough, wheezing, laryngitis, Shortness of breath, Headache, Nausea, Vomiting, narcosis, Lung irritation, chest pain, pulmonary edema, Central nervous system depression, Dermatitis, Gastrointestinal disturbance. |
| Methyl Ethyl Ketoxime(9 | 6-29-7) |
| LD50 Oral - Rat - Acute toxicity | 2,236 mg/kg, Oral - Rat - (OECD Test Guideline 401) |
| LC50 Inhalation - Rat - male & female | 4.83 mg/l, 4 h, Rat - male & female (OECD Test Guideline 403) |
| LD50 Dermal - Rabbit | 1,000 - 1,800 mg/kg |
| Skin | Skin - Rabbit Result: No skin irritation (OECD Test Guideline 404) |
| corrosion/irritation | · |
| Serious eye damage/eye irritation | Eyes - Rabbit Result- Risk of serious damage to eyes. (OECD Test Guideline 405) |
| Respiratory or skin sensitization | Buehler Test - Guinea pig May cause sensitization by skin contact. (OECD Test Guideline 406) |
| Germ cell mutagenicity | in vitro assay S. typhimurium Result: negative Drosophila melanogaster - male Result: negative. |
| Carcinogenicity | Limited evidence of carcinogenicity in animal studies IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. ACGIH: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by ACGIH. NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA. |
| Reproductive toxicity | No data available. |
| Specific target organ | No data available. |
| toxicity - single exposure | |
| Specific target organ toxicity - repeated exposure | No data available. |
| Aspiration hazard | No data available. |
| Additional Information | Repeated dose toxicity - Rat - male - Drinking - No observed adverse effect level - 25 mg/kg Repeated dose toxicity - Rat - male and female - inhalation (vapour) - No observed adverse effect level - 0.009 mg/kg RTECS: EL9275000 To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. |
| Phenylethane(100-41-4) | |
| LC50 (Mouse, Male) | 10 mg/l Assessment: The component/mixture is moderately toxic after short term inhalation. |
| LD50 (rabbit) | 15,433 mg/kg |
| Skin corrosion/irritation | Species: rabbit Result: Mild skin irritation |
| Serious eye | Species: rabbit Result: Mild eye irritation Remarks: No data available |
| damage/eye irritation | |
| Respiratory or skin sensitization | Remarks: No data available |
| Germ cell mutagenicity | Genotoxicity in vitro, Test Type: Chromosome aberration test in vitro Test species: Chinese hamster ovary (CHO) Metabolic activation: with and without metabolic activation Method: OECD Test Guideline 473 Result: negative GLP: no: Test Type: Mammalian cell gene mutation assay Test species: mouse lymphoma cells Metabolic activation: with and without metabolic activation Method: OECD Test Guideline 476 Result: negative GLP: yes Genotoxicity in vivo: Test Type: In vivo micronucleus test Test species: mouse (male) Application Route: Oral Method: OECD Test Guideline 474 Result: negative GLP: yes Test Type: DNA damage and/or repair Test species: mouse (male and female)Application Route: Inhalation Method: OECD Test Guideline 486 Result: negative GLP: yes Germ cell mutagenicity Assessment: In vivo tests did not show mutagenic effects |
| Carcinogenicity | Species: mouse, (male and female) Application Route: Inhalation Exposure time: 103 wk Activity duration: 6 h Dose: 0, 75, 250, 750 ppm Frequency of Treatment: 5 days/week NOAEL: 250 ppm Method: OECD Test Guideline 453 Result: evidence of carcinogenic activity Symptoms: increased incidences of alveolar/bronchiolar neoplasms, increase incidence of |

| | hepatocellular carcinomas GLP: yes Carcinogenicity - Assessment : Carcinogenicity | |
|--|---|--|
| | classification not possible from current data. | |
| Reproductive toxicity | Effects on fertility: Test Type: One generation study Species: rat, male and female Application Route: Inhalation Dose: 0, 100, 500 and 1000 ppm Duration of Single Treatment: 6 h General Toxicity - Parent: NOAEC: 1,000 ppm General Toxicity F1: NOAEC: 100 ppm Symptoms: Reduced foetal weight. Reduced offspring weight gain. Method: OECD Test Guideline 415 Result: No reproductive effects. GLP: yes Effects on foetal development: Species: rat Application Route: Inhalation Dose: 0, 100, 500, 1000, 2000 ppm Duration of Single Treatment: 15 d General Toxicity Maternal: NOAEC: 500 ppm Teratogenicity: NOAEC: 2,000 ppm Developmental Toxicity: NOAEC: 500 ppm Symptoms: Reduced body weight Method: OECD Test Guideline 414 Result: Developmental toxicity occurred at maternal toxicity dose levels GLP: No data available Reproductive toxicity - Assessment: No toxicity to reproduction Did not show teratogenic effects in animal experiments. | |
| STOT single exposure | No data available. | |
| STOT - single exposure STOT - repeated | Target Organs: Auditory system Assessment: May cause damage to organs through prolonged | |
| exposure | or repeated exposure., The substance or mixture is classified as specific target organ toxicant, repeated exposure, category 2. | |
| Repeated dose toxicity | Species: rat, male and female NOAEL: 75 mg/kg Application Route: Oral Exposure time: 28 d Dose: 75, 250 and 750 mg/kg bw/day Method: OECD Test Guideline 407 GLP: yes Symptoms: Increased kidney and liver weights | |
| Aspiration toxicity | May be fatal if swallowed and enters airways. | |
| Red Iron Oxide(1309-37 | , , | |
| LD50 Oral Bayferrox 130M - Rat | 5000 mg/kg - Rat | |
| Irritation/Corrosion | No Data Available | |
| Sensitization Chaptia Taxisity | No Data Available | |
| Chronic Toxicity | No Data Available | |
| Mutagenicity | No Data Available | |
| Carcinogenicity Product/ingredient | No Data Available No Data Available | |
| name | No Data Available No Data Available | |
| Specific Target Organ Toxicity (Single Exposure) | NO Data Available | |
| Specific Target Organ Toxicity (Repeated Exposure) | No Data Available | |
| Acute Toxicity Estimates | No Data Available | |
| Titanium Dioxide(13463 | -67-7) | |
| ORAL ALD (rat) | >2400 mg/kg | |
| Dermal ALD (rabbit) | >10000 mg/m3 | |
| Inhalation 4 h ALC | >6.82 mg/l | |
| Skin irritation | slight irritation | |
| Eye irritation | slight irritation | |
| Sensitsation | Did not cause sensitsation on laboratory animals. | |
| Carcinogenicity | In lifetime inhalation studies rats were exposed for 2 years to respectively 10, 50, 250 mg/m3 of respirable Ti02. | |
| Toluene(108-88-3) | > E E00 mg/kg | |
| LD50 (rat, male) LC50 (rat, male and | > 5,580 mg/kg 28.1 mg/l Exposure time: 4 h Test atmosphere: vapour Method: OECD Test Guideline 403 | |
| female) | | |
| LD50 (rabbit) Skin | > 5,000 mg/kg Species: rabbit Exposure time: 4 h Result: Irritating to skin. | |
| corrosion/irritation | | |
| Serious eye damage/eye irritation | Species: rabbit Result: Irritating to eyes. Method: OECD Test Guideline 405 | |
| Respiratory or skin sensitization | Test Type: Maximization Test (GPMT) Species: guinea pig Result: Did not cause sensitization on laboratory animals. GLP: yes | |
| Germ cell mutagenicity | Genotoxicity in vitro: Test Type: Mammalian cell gene mutation assay Test species: Mouse lymphoma cells Metabolic activation: with and without metabolic activation Method: OECD Test Guideline 476 Result: negative: Test Type: Ames test Metabolic activation: with and without metabolic activation Result: negative Genotoxicity in vivo: Test Type: Chromosome aberration assay in vivo Test species: rat Cell type: Bone marrow Application Route: Intraperitoneal Exposure time: 1 or 5 d Dose: 0, 0.025, 0.082, 0.247 ml/kg Result: negative Test Type: Dominant lethal assay Test species: mouse (male) Application Route: inhalation (vapour) Exposure time: 6 h/d, 5 d/wk for 8 wks Dose: 0, 100, 400 ppm Method: OECD Test Guideline 478 Result: negative Germ cell mutagenicity Assessment: Tests on bacterial or mammalian cell cultures did not show mutagenic effects. | |
| | manimalian cell cultures ald not snow mutagenic effects. | |

| Carcinogenicity | Species: rat, (male and female) Application Route: inhalation (vapour) Exposure time: 103 wks Dose: 0, 600, 1200 ppm Frequency of Treatment: 6.5 h/d, 5 d/wk NOAEL: No observed adverse effect level: 1,200 ppm Method: OECD Test Guideline 453 Result: did not display carcinogenic properties Symptoms: Erosion of nasal epithelium Species: rat, (male and female) Application Route: inhalation (vapour) Exposure time: 103 wks Dose: 0, 600, 1200 ppm Frequency of Treatment: 6.5 h/d, 5 d/wk NOAEL: No observed adverse effect level: 1,200 ppm Method: OECD Test Guideline 453 Result: did not display carcinogenic properties Symptoms: Erosion of nasal epithelium Species: rat, (male and female) Application Route: inhalation (vapour) Exposure time: 103 wks Dose: 0, 600, 1200 ppm Frequency of Treatment: 6.5 h/d, 5 d/wk NOAEL: No observed adverse effect level: 1,200 ppm Method: OECD Test Guideline 453 Result: did not display carcinogenic properties Symptoms: Erosion of nasal epithelium, GLP: yes, Carcinogen |
|--|---|
| Reproductive toxicity | Effects on fertility: Test Type: Two-generation study Species: rat, male and female Application Route: Inhalation Dose: 0, 100, 500, 2000 ppm Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: 500 ppm General Toxicity F1: NOAEC: 500 ppm Fertility: NOAEC: 2,000 ppm Symptoms: Reduced maternal body weight gain. Reduced offspring weight gain. Method: OECD Test Guideline 416 Result: Animal testing did not show any effects on fertility. GLP: yes Test Type: Fertility Species: rat, male and female Application Route: inhalation (vapour) Dose: 0, 600, 1200 ppm Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: 600 ppm Symptoms: Decreased sperm count Result: Animal testing did not show any effects on fertility. |
| Reproductive toxicity (cont.) | Effects on fetal development: Species: rat Application Route: inhalation (vapour) Dose: 0, 250, 750, 1500, 3000 ppm Duration of Single Treatment: 10 d Frequency of Treatment: 6 hr/day General Toxicity Maternal: NOAEC: 750 ppm Developmental Toxicity: NOAEC: 750 ppm Symptoms: Maternal toxicity, Reduced body weight, Skeletal malformations. GLP: yes Reproductive toxicity - Assessment: Some evidence of adverse effects on sexual function and fertility, and/or on development, based on animal experiments. |
| STOT - single exposure | Exposure routes: Target Organs: Assessment: Remarks: Inhalation Central nervous system May cause drowsiness or dizziness. The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with narcotic effects. |
| STOT - repeated | Inhalation Auditory system, Eyes May cause damage to organs through prolonged or repeated |
| exposure | exposure., The substance or mixture is classified as specific target organ toxicant, repeated |
| - SAPOSAI C | exposure, category 2. |
| Repeated dose toxicity | Species: mouse, male and female NOAEL: 625 mg/kg LOAEL: 1,250 mg/kg Application Route: Oral Exposure time: 13 wks Number of exposures: 5 d/wk Dose: 312, 625, 1250, 2500, 5000 Group: yes GLP: yes Symptoms: death, Increased liver weight, ataxia, hyperactivity, hypothermia Species: rat, male and female NOAEL: 300 Application Route: inhalation (vapour) Exposure time: 6, 12, or 18 months Number of exposures: 6 h/d, 5 d/wk Dose: 0, 30, 100, 300 ppm Method: OECD Test Guideline 453 Repeated dose toxicity - Assessment: Causes skin irritation. |
| Aspiration toxicity | Aspiration Toxicity - Category 1 |
| Further information | Remarks: Symptoms of overexposure may be headache, dizziness, tiredness, nausea and vomiting. Concentrations substantially above the TLV value may cause narcotic effects. Solvents may degrease the skin. |
| Triethylamine(121-44-8) | |
| LD50 Oral - Rat - Acute toxicity | 730 mg/kg, Oral - Rat, (OECD Test Guideline 401) |
| LD50 Inhalation - Rat | 7.31 mg/l, Inhalation - Rat- 4 h, (OECD Test Guideline 403) |
| LD50 Inhalation - Rabbit | 580 mg/kg, Oral - Rabbit, (OECD Test Guideline 402) |
| Skin corrosion/irritation | Skin - Rabbit Result: Extremely corrosive and destructive to tissue. (OECD Test Guideline 404) |
| Serious eye | Eyes - Rabbit Result - Risk of serious damage to eyes. (OECD Test Guideline 405) |
| damage/eye irritation | |
| Respiratory or skin sensitization | in vivo assay - Guinea pig Result: Did not cause sensitization on laboratory animals. |
| Germ cell mutagenicity | No data available. |
| Carcinogenicity | Carcinogenicity IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC. NTP: No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP. OSHA: No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA. |
| Reproductive toxicity | No data available. |
| Specific target organ toxicity - single exposure | Inhalation - May cause respiratory irritation. |
| Specific target organ toxicity - repeated exposure | No data available. |

| Additional Information Additi | Aspiration bazard | No data available |
|--|------------------------|--|
| upper respiratory tract, eyes, and skin, spasm, inflammation and edem of the bornchit, pneumonits, pulmonary edema, burning sensation, Cough, wheezing, Jaryngitis, Shortness of breath, Headache, Nausea, Voniting To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evide | Aspiration hazard | No data available. |
| spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema, burning sensation, Cough, wheezing, laryngitis, Shortness of breath, Headednée, Nausea, vorniting To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Joseph Common Common Common Central nervous system - Irregularities - Based on Human Evidence Joseph Common Common Common Common Central nervous system - Irregularities - Based on Human Evidence Joseph Common | Additional Information | |
| spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema, burning sensation, Cough, wheezing, laryngitis, Shortness of breath, Headednée, Nausea, vorniting To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Joseph Common Common Common Central nervous system - Irregularities - Based on Human Evidence Joseph Common Common Common Common Central nervous system - Irregularities - Based on Human Evidence Joseph Common | | upper respiratory tract, eyes, and skin., spasm, inflammation and edema of the larynx, |
| sensation, Cough, wheezing, laryngitis, Shortness of breath, Headache, Nausea, Vomiting To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Species: rabbit Exposure time: 4 h Test atmosphere: vapour Method: OECD Test Guideline 402 GLP: yes Central nervous Species: rabbit Exposure time: 4 h Classification: Irritating to skin Result: Irritating to skin Genrosion/irritation - Irritating to eyes Exposure time: 1 - 2 s Classification: Not irritation or skin service or skin ser | | spasm, inflammation and edema of the bronchi, pneumonitis, pulmonary edema, burning |
| the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Central nervous system - Irregularities - Based on Human Evidence VMBP Naphtha(64742-88-9) LDS0 Oral (rat, male and female) LCS0 Inhalation (rat) - 7.6 mg/l Exposure time: 4 h Test atmosphere: vapour Method: OECD Test Guideline 403 GLP: yeas and female) LDS0 Dermal (rabbit, male and female) - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes Toxibal and female) - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes Toxibal and female) - 5,5000 mg/kg Method: OECD Test Guideline 402 GLP: yes Toxibal and female) - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes Toxibal and female) - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes GIP: yes - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes GIP: yes - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes - 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes Remarks: not sensitizing. - 2,000 mg/kg Method: OECD Test Guideline 472 Result: Did not cause sensitization on laboratory animals. GLP: yes Remarks: not sensitizing. - 3,000 mg/kg Method: OECD Test Guideline 474 Result: negative GLP: No data available: Test - 4,000 mg/kg Method: OECD Test Guideline 474 Result: negative GLP: No data available: Test - 4,000 mg/kg Method: OECD Test Guideline 475 Result: negative GLP: No Gata available: Test - 4,000 mg/kg Method: OECD Test Guideline 476 Result: negative GLP: No Gata available: Test - 5,000 mg/kg Method: OECD Test Guideline 476 Result: negative GLP: No Gata available: Test - 5,000 mg/kg Method: OECD Test Guideline 476 Result: No Meth | | sensation Cough wheezing laryngitis Shortness of breath Headache Nausea Vomiting To |
| thoroughly investigated. Central nervous system - Irregularities - Based on Human Evidence Central nervous system - Irregularities - Based on Human Evidence LOSO Oral (rat, male and female) LOSO Oral (rat, male and female) LOSO Inhalation (rat, male and female) LOSO Dermal (rabbit, western facilities) LOSO Dermal (rabbit) LOSO Dermal (ra | | |
| Central nervous system - 1 regularities - 8 ased on Human Evidence | | |
| VMBP Naphtha(64742-89-8) LD50 Oral (rat, male and female) LS50 Oral (rat, male and female) LS50 Drain (rabbit, male and female) LS50 Derma (rabbit, male and female) Serious eye Serious eye damage/eye irritation GJP: yes Serious eye damage/eye irritation Respiratory or skin Respiratory or skin Respiratory or skin Sensitization Germ cell mutagenicity Respiratory or skin Resp | | |
| LC50 Inhalation (rat, male and female) Skin or male and female or female and fe | | |
| LC50 Inhalation (rat, male and female) Skin or male and female or female and fe | VM&P Naphtha(64742-8 | 9-8) |
| and female) LC50 Inhalation (rat, male and female) LC50 Inhalation (rat, male and female) LD50 Dermal (rabbit, male and female) LD50 Dermal (rabbit, male and female) Skin corrosion/irritation Serious eye damage/eye irritation Respiratory or skin sensitization Respiratory or skin sensitization Germ cell mutagenicity Germ cell mutagenicity Germ cell mutagenicity Fermal and without metabolic activation with and without metabolic activation: with and without metabolic activation of the contoxicity in vitro : Test Type: Arms test Metabolic activation: with and without metabolic activation with and without metabolic activation with and without metabolic activation of the contoxicity in vitro : Test Type: In vivro infraorucieus test species: Arbeit (male and female) Application Route: Inhalation Exposure time: 10 hours/day Dose: 0, 2000 1, 10000, 20000 mg/m3 Result: negative GEP: no Germ cell mutagenicity Assessment: Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity Reproductive toxicity Application Route: Inhalation Exposure time: 10 with December 10 in not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Personation of the semants: Category 1B Effects on fertility: Test Type: Two-generation study Species: rat, male and female application Route; cernal Exposure time: 102 wk Dose: 0, 2000 mg/m3 Capitation Route; cernal Exposure time: 102 wk Dose: 0, 2000 mg/m3 Capitation Route; cernal Exposure time: 102 wk Dose: 0, 2000 mg/m3 Capitation Route; cernal Poxicity Fix (Male 2) and poxicity in Route; and poxicity in R | | |
| LCS0 Inhalation (ret. male and female) LD50 Dermal (rabbit, male and female) Skin Species: rabbit Exposure time: 4 h Test atmosphere: vapour Method: OECD Test Guideline 403 GLP; yes male and female) Skin Species: rabbit Exposure time: 4 h Classification: Irritating to skin Result: Irritating to skin GDP; yes Serious eye Species: rabbit Result: Not irritating to eyes Exposure time: 1 - 2 s Classification: Not GDP; yes Species: rabbit Result: Not irritating to eyes Exposure time: 1 - 2 s Classification: Not GDP; yes Semarks; No eye Irritation Respiratory or skin sensitization result: Did not cause sensitization on laboratory animals. GDP; yes Remarks; not sensitization. Germ cell mutagenicity Genotoxicity in vitro: 1 Test Type: Ames test Metabolic activation: with and without metabolic activation without metabolic activation without metabolic activation with and without metabolic activation method: OECD Test Guideline 473 Result: negative GLP; No data available: Test Type: Mammalian cell gene mutation assay Test species: Mouse lymphoma cells Metabolic activation with and without metabolic activation method: OECD Test Guideline 476 Result: negative GLP; No data available and memale Application Route: Demand Exposure time: 10 hours day Dose: 0, 2000, 1000, 2000 mg/m3 Result: negative GLP; yes Germ cell mutagenicity Assessment: Did not neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP; No data available Remarks: Category 18 Reproductive toxicity Effects on Fertility: 1 Test Type: Two-generation study Species; rat, male and female Application Route: Inhalation Tose; 5,500,700,000,000,000 mg/m3 Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity + Parent: NOAEC: 2,000 mg/m3 Symptoms: No ada available Remarks: Category 18 Effects on Fertility: 1 Test Type: Two- | | , c, |
| male and female) LD50 Dermal (rabbit, male and female) Skin Corrosion/irritation Species: rabbit Exposure time: 4 h Classification: Irritating to skin Result: Not irritating to eyes Exposure time: 1 - 2 s Classification: Not irritating to eyes GLP: yes Semarks: No eye irritation Respiratory or skin Sensitization Respiratory or skin Sensitization Result: Did not cause sensitization on laboratory animals. GLP: yes Remarks: not sensitizition. Result: negative GLP: No data available: Test Type: Mammalian cell gene mutation assay Test species: Mouse lymphoma cell series in egative GLP: No data available: Test Type: Mammalian cell gene mutation assay Test species: Mouse lymphoma cells in the data available and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GLP: No data available: Test Type: Mammalian cell gene mutation assay Teye: In vivo mittagenicity Assay Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GLP: No data available and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GLP: No description on show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carclinogenicity Reproductive toxicity Application Route: Evaluation Route: Emparia Exposure time: 10 wk Dose: 0.05 ml neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 1B Effects on fertility: Test Type: Two-generation study Species: rat, male and female Application Route: 20,000 mg/m3 Symptoms: No adverse effects application Route: 20,000 mg/m3 Symptoms: No adverse effects application Route: Description and Application Route: 20,000 mg/m3 Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NoAEL: 23,900 mg/m3 Duration of Single Treatment: 6 h Frequency | | 7.6 mg/l Exposure time: 4.6 Test atmosphere: vapour Method: OECD Test Guideline 403 CLD: |
| LD50 Dermal (rabbit, page and memale) Skin | | · · · · · · · · · · · · · · · · · · · |
| male and female) Skin corrosion/irritation Schin Species: rabbit Exposure time: 4 h Classification: Irritating to skin Result: Irritating to skin Result: Irritating to skin Result: Irritating to skin Result: Not irritating to eyes Exposure time: 1 - 2 s Classification: Not irritating to eyes GLP: yes Remarks: No eye irritation Respiratory or skin Result: Did not cause sensitization on laboratory animals. GLP: yes Remarks: not sensitization. Result: Did not cause sensitization on laboratory animals. GLP: yes Remarks: not sensitization activation with an unitation assay Test species: Mouse Imphoratory with an unitation assay Test species: Mouse Imphoratory with an unitation assay Test species: Mouse Imphoratory animals. GLP: yes Remarks: not sensitization activation: with and without metabolic activation with and without metabolic activation with and without metabolic activation Method: DECD Test Guideline 471 Result: negative GLP: No data available: Test Type: Mammalian cell gene mutation assay Teye: In vivo micronucleus test Berdies: Test (male and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 1000, 20000 mg/m3 Result: negative GLP: yee Germ cell mutagenicity Assay (male) Application Route: Demal Exposure time: 102 wk Dose: 0.05 ml neat Method: OECD Test Guideline 438 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 18 Reproductive toxicity Reproduct | | |
| Skin of protection of the prot | , | > 2,000 mg/kg Method: OECD Test Guideline 402 GLP: yes |
| Gerrous Gerr | male and female) | |
| Gerrous Gerr | Skin | Species: rabbit Exposure time: 4 h Classification: Irritating to skin Result: Irritating to skin |
| Secious eye damage/eye irritation Respiratory or skin Respiratory a minals. GPI: yes Remarks: not sensitization Respiratory a minals and plane mutation assay Test species: Mouse lymphoma cells Metabolic activation: with and without metabolic activation with one with and without metabolic activation with one of CPC Test Guideline 475 Result: negative GIP: no Genotoxicity in vivo: Test Type: In vivo micronucleus test species: rat (male and female) Application Route: Inhalation Exposure time: 6 hours of the company of the c | _ | |
| Gamage/eye irritation Frest Type: Bueller Test Species: guinea pig Assessment: Does not cause skin sensitization Respiratory or skin Sensitization Result: Did not cause sensitization on laboratory animals. G.P.P. yes Remarks: not sensitization Result: Did not cause sensitization on laboratory animals. G.P.P. yes Remarks: not sensitizing Gentoxicity in vitro: Test Type: Ames test Metabolic activation with and without metabolic activation Method: OECD Test Guideline 471 Result: negative G.P.P. No data available: Test Type: Mammalian cell gene mutation assay Test species: Mouse lymphoma cells Metabolic activation: with and without metabolic activation Method: OECD Test Guideline 476 Result: negative G.P.P. no Gentoxicity in vivo: Test Type: In vivo micronucleus test species: rat (male and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative G.P.P. yes Germ cell mutagenicity Assessment: Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity | | |
| Respiratory or skin sensitization results: Did not cause sensitization results: Did not cause sensitization on laboratory animals. GIP: yes Remarks: not sensitizing. Germ cell mutagenicity Germ cell cell cell cell cell cell cell cel | | |
| Result: Did not cause sensitization on laboratory animals. GLP: yes Remarks: not sensitizing contoxicity in vitro: Test Type: Ame stex Metabolic activation: with authorus metabolic activation Method: OECD Test Guideline 471 Result: negative GLP: No data available: Test price: Mammalian cell gene mutation assay Test species: Rouse lymphoma cells Metabolic activation: with and without metabolic activation Method: OECD Test Guideline 476 Result: negative GLP: no Genotoxicity in vivo: Test Type: In vivo micronucleus respecies: rat (male and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GLP: yes Germ cell mutagenicity Assessment: Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity | | |
| Gentoxicity in vitro : Test Type: Ames test Metabolic activation with and without metabolic activation script of the rest Guideline 471 Result: negative GIP: No data available : Test Type: Mammalian cell gene mutation assay Test species: Mouse lymphoma cells Metabolic activation with and without metabolic activation Method: OFCD Test Guideline 476 Result: negative GIP: no Genotoxicity in vivo : Test Type: In vivo micronucleus test species: rat (male and female) Application Route: Inhalation Exposure time: 102 wk Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GIP: yes Germ cell mutagenicity Assessment : Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity Carcinogenicity Expecies: mouse, (male) Application Route: Dermal Exposure time: 102 wk Dose: 0.05 ml neat Method: OFCD Test Guideline 453 Result: did not display carcinogenic properties GIP: No data available Remarks: Category 18 Reproductive toxicity Effects on fertility: Test Type: Two-generation study Species: rat, male and female Applications Route: vapour Dose: 0, 5000, 10000, 20000 mg/m3 Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m3 General Toxicity F11: NOAEC: > 20,000 mg/m3 Symptoms: No adverse effects. Method: OECD Test Guideline 416 GIP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m3 Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m3 Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GIP: yes EXPOSURE PARENT PAR | Respiratory or skin | Test Type: Buehler Test Species: guinea pig Assessment: Does not cause skin sensitization. |
| Gentoxicity in vitro : Test Type: Ames test Metabolic activation with and without metabolic activation script of the rest Guideline 471 Result: negative GIP: No data available : Test Type: Mammalian cell gene mutation assay Test species: Mouse lymphoma cells Metabolic activation with and without metabolic activation Method: OFCD Test Guideline 476 Result: negative GIP: no Genotoxicity in vivo : Test Type: In vivo micronucleus test species: rat (male and female) Application Route: Inhalation Exposure time: 102 wk Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GIP: yes Germ cell mutagenicity Assessment : Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity Carcinogenicity Expecies: mouse, (male) Application Route: Dermal Exposure time: 102 wk Dose: 0.05 ml neat Method: OFCD Test Guideline 453 Result: did not display carcinogenic properties GIP: No data available Remarks: Category 18 Reproductive toxicity Effects on fertility: Test Type: Two-generation study Species: rat, male and female Applications Route: vapour Dose: 0, 5000, 10000, 20000 mg/m3 Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m3 General Toxicity F11: NOAEC: > 20,000 mg/m3 Symptoms: No adverse effects. Method: OECD Test Guideline 416 GIP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m3 Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m3 Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GIP: yes EXPOSURE PARENT PAR | sensitization | Result: Did not cause sensitization on laboratory animals. GLP: yes Remarks: not sensitizing. |
| activation Method: DECD Test Guideline 471 Result: negative GLP: No data available: Test Type: Mammalian cell gene mutation assay Test species: Mouse lymphoma cells Metabolic activation: with and without metabolic activation Method: OECD Test Guideline 476 Result: negative GLP: no Genotoxicity in vivo : Test Type: In vivo micronucle sets species: rat (male and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GLP: yes Germ cell mutagenicity Assessment: Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity Carcinogenicity Species: mouse, (male) Application Route: Dermal Exposure time: 102 wk Dose: 0.05 ml neat Method: OECD Test Guideline 435 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 18 Reproductive toxicity Reproductive toxicity Fifects on fertility: Test Type: Two-generation study Species: rat, male and female Application Route: vapour Dose: 0, 5000, 10000, 20000 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEC: > 20,000 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure STOT - single exposure STOT - repeated exposure streament: 7 days/week General Toxicity Maternal: NOAEC: > 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes Steposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male and female NOAEC: 1402 Application Route: Inhalation (application Route: Inhal | | Genotoxicity in vitro: Test Type: Ames test Metabolic activation; with and without metabolic |
| Type: Mammalian cell gene mutation assay Test species: Mouse lymphoma cells Metabolic activation swith and without metabolic activation Method: OECD Test Guideline 476 Result: negative GLP; no Genotoxicity in vivo : Test Type: In vivo micronucleus test species: rat (male and female) Application Route: Inhalation Exposure time: 6 horourglay Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GLP; yes Germ cell mutagenicity Assessment : Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Species: mouse, (male) Application Route: Dermal Exposure time: 10.0 wk Dose: 0.05 ml neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 18 Reproductive toxicity Beffects on fertility: Test Type: Two-generation study Species: rat, male and female Application Route: vapour Dose: 0, 5000, 1,0000, 20000 mg/m³ Dynation of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Synation of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAE: 23,900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAE: 23,900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAE: 23,900 mg/m³ Symptoms: No adminishments of NoAE: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure Exposure Exposure Exposure Exposur | Germ cen matagement | |
| activation: with and without metabolic activation Method: OECD Test Guideline 476 Result: negative GIP: no Genotoxicity in vivo: 1 Test Type: In vivo micronucleus test species: rat (male and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GIP: yes Germ cell mutagenicity Assessment: Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity Species: mouse, (male) Application Route: Dermal Exposure time: 102 wk Dose: 0.05 ml neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 1B Reproductive toxicity Reproductive toxicity: Toxicity Fig. 1000, 1000, 20000 mg/m³ Duration of Single Freatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 EIP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration | | |
| negative GLP: no Genotoxicity in vivo : Test Type: In vivo micronucleus test species: rat (male and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GLP: yes Germ cell mutagenicity Assessment : Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity Species: mouse, (male) Application Route: Dermal Exposure time: 102 wk Dose: 0.05 ml neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 1B Reproductive toxicity Reproductive toxicity Effects on fertility: Test Type: Two-generation study Species: rat, male and female Application Route: vapour Dose: 0, 5000, 10000, 20000 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 414 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Toxicity Metamal: NOAEC: > 20,000 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day. 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 existion Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target O | | |
| (male and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GEP; yes Germ cell mutagenicity Assessment: Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity Species: mouse, (male) Application Route: Dermal Exposure time: 102 wk Dose: 0.05 ml neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 1B Reproductive toxicity Reproductive toxicity Frestment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: 5 species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute dermal toxicity. Acute toxic | | |
| (male and female) Application Route: Inhalation Exposure time: 6 hours/day Dose: 0, 2000, 10000, 20000 mg/m3 Result: negative GEP; yes Germ cell mutagenicity Assessment: Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. Carcinogenicity Species: mouse, (male) Application Route: Dermal Exposure time: 102 wk Dose: 0.05 ml neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 1B Reproductive toxicity Reproductive toxicity Frestment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: 5 species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute dermal toxicity. Acute toxic | | negative GLP: no Genotoxicity in vivo: Test Type: In vivo micronucleus test species: rat |
| 10000, 20000 mg/m3 Result: negative GEP; yes Germ cell mutagenicity Assessment: Did not show carcinogenic, teratogenic or mutagenic effects in animal experiments. | | |
| Show carcinogenic, teratogenic or mutagenic effects in animal experiments. Species: mouse, (male) Application Route: Dermal Exposure In: 102 wk Dose: 0.05 ml neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 1B Reproductive toxicity Effects on fertility: Test Type: Two-generation study Species: rat, male and female Application Route: vapour Dose: 0, 5000, 10000, 20000 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity; NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute toxicity estimate, 4631 ppm Exposure time, 4 h Te | | |
| Species: mouse, (male) Application Route: Dermal Exposure time: 102 wk Dose: 0.05 ml neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 1B | | |
| neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: No data available Remarks: Category 1B Reproductive toxicity Fifects on fertility: Test Type: Two-generation study Species: rat, male and female Application Route: vapour Dose: 0, 5000, 10000, 20000 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity.: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure STOT - repeated Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Acute toxicity Product Acute inhalation Acute inhalation Acute inhalation Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Oral LC50 (rat, male) Oral Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate: 3,523 mg/kg Method: Calculation method: Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate: 4 h M | | |
| Reproductive toxicity Reproductive toxicity reproduct Reproductive toxicity extimate, 4631 ppm Exposure time; 3,523 mg/kg Method: Calculation method. Reproductive toxicity extimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Reproductive toxicity estimate in 1,100 mg/kg Method: Expert judgment. Reproductive toxicity estimate in 1,100 mg/kg Method: Expert judgment. Reproductive toxicity estimate in 1,100 mg/kg Method: Reproductive toxicity of 1,548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, | Carcinogenicity | |
| Reproductive toxicity Application Route: vapour Dose: 0, 5000, 10000, 20000 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. STOT - repeated exposure Repeated dose toxicity Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Xylene(1330-20-7) Acute toxicity Product Acute inhalation Acute toxicity product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation Acute oxicity estimate: 4,51100 mg/kg Method: Expert judgment. LC50 (rat, male) Inhalation Calculation method. Acute toxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (rat, male) Oral Acute doxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (rat, male) Oral Acute toxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (rat, male) Oral Acute toxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (rat, male) Oral Acute toxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (| | neat Method: OECD Test Guideline 453 Result: did not display carcinogenic properties GLP: |
| Reproductive toxicity Application Route: vapour Dose: 0, 5000, 10000, 20000 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. STOT - repeated exposure Repeated dose toxicity Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Xylene(1330-20-7) Acute toxicity Product Acute inhalation Acute toxicity product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation Acute oxicity estimate: 4,51100 mg/kg Method: Expert judgment. LC50 (rat, male) Inhalation Calculation method. Acute toxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (rat, male) Oral Acute doxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (rat, male) Oral Acute toxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (rat, male) Oral Acute toxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (rat, male) Oral Acute toxicity estimate: 4,51100 mg/kg Method: Expert judgment. CS0 (| | No data available Remarks: Category 1B |
| Application Route: vapour Dose: 0, 5000, 10000, 20000 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity.: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure STOT - repeated exposure Repeated dose toxicity Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration Toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute inhalation corrosion/irritation Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method: Calculation method. Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. 3,523 mg/kg Method: EU Method B.1 (Acute Toxicity, Oral) Target Organs: Kidney, Bladder GLP: no G700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category Species: rabbit Result: Mild eye irritation Remarks: No data available | Reproductive toxicity | |
| Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEC: 3,900 mg/m³ Embryo-fetal toxicity.: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Acute toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Oral CFO (rat, male) Oral GFO ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: | Reproductive toxicity | |
| 20,000 mg/m³ General Toxicity F1: NOAEC: > 20,000 mg/m³ Symptoms: No adverse effects. Method: OECD Test Guideline 416 GLP: yes Effects on fetal development : Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Acute toxicity Product Acute inhalation Acute dermal toxicity Acute dermal toxicity Acute dermal toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute dermal toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | | |
| Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity.: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Xylene(1330-20-7) Acute toxicity Product Acute inhalation Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute dermal toxicity Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Inhalation 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Remarks: No data available | | |
| Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity.: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. STOT - repeated exposure Repeated dose toxicity Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration Toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation Calculation method. Acute dermal toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. 3,523 mg/kg Method: EU Method B.1 (Acute Toxicity, Oral) Target Organs: Kidney, Bladder GLP: no 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin corrosion/irritation Serious eye damage/eye irritation Remarks: No data available | | |
| 6 n Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 10000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration toxicity Xylene(1330-20-7) Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute dermal toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Oral C50 (rat, male) Oral C50 (rat, male) Oral C50 (rat, male) G700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin corrosion/irritation Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Remarks: No data available | | Method: OECD Test Guideline 416 GLP: yes Effects on fetal development: Species: rat |
| 6 n Frequency of Treatment: 7 days/week General Toxicity Maternal: NOAEL: 23,900 mg/m³ Embryo-fetal toxicity: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 10000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration toxicity Xylene(1330-20-7) Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute dermal toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Oral C50 (rat, male) Oral C50 (rat, male) Oral C50 (rat, male) G700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin corrosion/irritation Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Remarks: No data available | | Application Route: Inhalation Dose: 2653, 7960, 23900 mg/m³ Duration of Single Treatment: |
| Embryo-fetal toxicity: NOAEL: 23,900 mg/m³ Symptoms: No malformations were observed. Method: OECD Test Guideline 414 GLP: yes STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Acute toxicity Product Acute oral toxicity : Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute dermal toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Oral C50 (rat, male) Oral C50 (rat, male) Thalation Inhalation S723 mg/kg Method: EU Method B.1 (Acute Toxicity, Oral) Target Organs: Kidney, Bladder GIP: no G60P: no G700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin Corrosion/irritation Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | | |
| STOT - single exposure | | |
| STOT - single exposure Exposure routes: Inhalation Target Organs: Central nervous system Assessment: May cause drowsiness or dizziness. No data available. Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute toxicity product Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Oral LC50 (rat, male) Oral C50 (rat, male | | |
| drowsiness or dizziness. STOT - repeated exposure Repeated dose toxicity Repeated dose toxicity Repeated dose toxicity Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product | | |
| STOT - repeated exposure Repeated dose toxicity Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration Toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute toxicity Product Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method: Calculation method. Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method: Calculation method. Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Oral LC50 (rat, male) Oral LC50 (rat, male) Inhalation Acute toxicity estimate: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin Corrosion/irritation Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | STOT - single exposure | |
| Repeated dose toxicity Repeated dose toxicity Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration Toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation Acute dermal toxicity Calculation method. Acute dermal toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Oral LC50 (rat, male) Oral Inhalation Acute toxicity estimate: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category Skin Corrosion/irritation Serious eye Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | | drowsiness or dizziness. |
| Repeated dose toxicity Repeated dose toxicity Species: rat, male NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Xylene(1330-20-7) Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute dermal toxicity Calculation method. Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Oral LC50 (rat, male) Inhalation Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Inhalation Acute toxicity estimate: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category Skin Corrosion/irritation Serious eye Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | STOT - repeated | No data available. |
| Repeated dose toxicity and female NOAEL: < 500 mg/kg Application Route: Oral Exposure time: 4 wk Number of exposures: nephropathy 64742-89-8: Repeated dose toxicity and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 Repeated dose | I - | |
| of exposures: 5 d/wk Dose: 500 or 2000 mg/kg/day Symptoms: nephropathy 64742-89-8: Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Xylene(1330-20-7) Acute toxicity Product Acute inhalation toxicity Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Oral LC50 (rat, male) Inhalation Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | | Species, rat, male NOAEL > 500 mg/kg Application Poute, Oral Expecure time, 4 wk Number |
| Species: rat, male and female NOAEL: 1402 Application Route: inhalation (vapour) Test atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration Toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute dermal toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Oral 3,523 mg/kg Method: EU Method B.1 (Acute Toxicity, Oral) Target Organs: Kidney, Bladder GLP: no 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | Repeated dose toxicity | |
| atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Aspiration Toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation toxicity Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Inhalation Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. LC50 (rat, male) Inhalation Acute toxicity estimate: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin Corrosion/irritation Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | | |
| days/week Material Safety Data Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 10000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration toxicity Xylene(1330-20-7) Acute toxicity Product Acute inhalation toxicity Acute dermal toxicity Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Inhalation Inhalation Skiin Corrosion/irritation Serious eye damage/eye irritation Respiratory or skin Aspiration Toxicity Date Sheet VM&P Naphtha Version 1.2 Revision Date: 08/11/2014 MSDS Number: 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney, Sheep Sheet Sheet Sheet Sheet Sheep Sheet Sheep Sheep Sheet Sheet Sheep Sheet Sheep Sheet Sheep Sheep Sheet Sheep Sheep Sheet Sheet Sheep Sheep Sheep Sheet Sheep Sheep Sheet Sheep Sheep Sheet Sheep She | | |
| Aspiration toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute inhalation toxicity Acute dermal toxicity Calculation method. Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Inhalation Inhalation Skin Corrosion/irritation Serious eye damage/eye irritation Respiratory or skin Aspiration 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration 222, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration 24, 523 mg/kg Method: Category 1 Acute toxicity - Category 1 Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute | | atmosphere: vapour Exposure time: 13 weeks Number of exposures: 6 hours/day, 5 |
| Aspiration toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute inhalation toxicity Acute dermal toxicity Calculation method. Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Inhalation Inhalation Skin Corrosion/irritation Serious eye damage/eye irritation Respiratory or skin Aspiration 100000002744 30 / 44 VM&P Naphtha Dose: 322, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration 222, 1402, 9869 mg/m3 GLP: yes Target Organs: Kidney Symptoms: Nasal and ocular discharge. Aspiration 24, 523 mg/kg Method: Category 1 Acute toxicity - Category 1 Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute | | |
| Aspiration toxicity Aspiration Toxicity - Category 1 Xylene(1330-20-7) Acute toxicity Product Acute inhalation toxicity Acute dermal toxicity Calculation method. Acute dermal toxicity Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. C50 (rat, male) Oral C50 (rat, male) Inhalation Acute toxicity estimate: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | | |
| Aspiration toxicity Xylene(1330-20-7) Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation toxicity Acute dermal toxicity Calculation method. Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Inhalation Inhalation Serious eye damage/eye irritation Respiratory or skin Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute Toxicity, Oral) Target Organs: Kidney, Bladder GLP: no 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | | |
| Acute toxicity Product Acute inhalation toxicity Acute dermal toxicity LC50 (rat, male) Inhalation Inhalation Skin Corrosion/irritation Respiratory or skin Acute oral toxicity : Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute dermal toxicity Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Calculation method. Acute toxicity estimate : 3,523 mg/kg Method: Expert judgment. 3,523 mg/kg Method: Expert judgment. 4,020 pg mg/kg Method: Expert judgment. 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, available assessment in the substance or mixture is classified as specific target organ toxicant, available assessment in the substance or mixture is classified as specific target organ toxicant, available assessment in the substance or mixture is classified as specific target organ toxicant, availabl | A projugation as 1000 | |
| Acute toxicity Product Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. Acute inhalation toxicity Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Inhalation Inhalation Serious eye damage/eye irritation Respiratory or skin Acute toxicity: Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. Acute toxicity estimate: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 h Result: Irritating to ski | | Aspiration Toxicity - Category 1 |
| Acute inhalation toxicity Acute dermal toxicity Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Inhalation Skin corrosion/irritation Respiratory or skin Remarks: No data available Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. 3,523 mg/kg Method: EU Method B.1 (Acute Toxicity, Oral) Target Organs: Kidney, Bladder GLP: no 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin corrosion/irritation Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | Xylene(1330-20-7) | |
| Acute inhalation toxicity Acute dermal toxicity Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) Inhalation Skin corrosion/irritation Respiratory or skin Remarks: No data available Acute toxicity estimate, 4631 ppm Exposure time, 4 h Test atmosphere: gas Method; Calculation method. Acute toxicity estimate : 1,100 mg/kg Method: Expert judgment. 3,523 mg/kg Method: EU Method B.1 (Acute Toxicity, Oral) Target Organs: Kidney, Bladder GLP: no 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin corrosion/irritation Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | Acute toxicity Product | Acute oral toxicity: Acute toxicity estimate: 3,523 mg/kg Method: Calculation method. |
| toxicity Acute dermal toxicity LC50 (rat, male) Oral LC50 (rat, male) LC50 (rat, male) C50 (rat, male) | | |
| Acute dermal toxicity LC50 (rat, male) Oral CC50 (rat, male) Oral Sinhalation Serious eye damage/eye irritation Respiratory or skin Acute toxicity estimate: 1,100 mg/kg Method: Expert judgment. 3,523 mg/kg Method: EU Method B.1 (Acute Toxicity, Oral) Target Organs: Kidney, Bladder GLP: no 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin | | |
| LC50 (rat, male) Oral LC50 (rat, male) LC50 (rat, male) Inhalation Skin corrosion/irritation Serious eye damage/eye irritation Respiratory or skin 3,523 mg/kg Method: EU Method B.1 (Acute Toxicity, Oral) Target Organs: Kidney, Bladder GLP: no 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | | |
| CC50 (rat, male) Inhalation Skin corrosion/irritation Serious eye damage/eye irritation GLP: no 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin Corrosion/irritation Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | | |
| CC50 (rat, male) Inhalation Skin corrosion/irritation Serious eye damage/eye irritation GLP: no 6700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin Corrosion/irritation Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | LC50 (rat, male) Oral | 3,523 mg/kg Method: EU Method B.1 (Acute Toxicity, Oral) Target Organs: Kidney, Bladder |
| LC50 (rat, male) Inhalation Skin corrosion/irritation Respiratory or skin Remarks: No data available Rosessment G700 ppm Exposure time: 4 h Method: Directive 67/548/EEC, Annex V, B.2. GLP: No data available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin Corrosion/irritation Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | | |
| Inhalation available Assessment: The substance or mixture is classified as specific target organ toxicant, single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | LC50 (rat_male) | |
| single exposure, category 3 with respiratory tract irritation. Remarks: Acutely Toxic Category 4 Skin corrosion/irritation Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | | |
| Skin Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | IIIIaiation | |
| Skin Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation, Category 2 Serious eye Species: rabbit Result: Mild eye irritation Respiratory or skin Remarks: No data available | | |
| corrosion/irritation Category 2 Serious eye Species: rabbit Result: Mild eye irritation damage/eye irritation Respiratory or skin Remarks: No data available | | |
| corrosion/irritation Category 2 Serious eye Species: rabbit Result: Mild eye irritation damage/eye irritation Respiratory or skin Remarks: No data available | Skin | Species: rabbit Exposure time: 24 h Result: Irritating to skin Remarks: Skin irritation. |
| Serious eye damage/eye irritation Respiratory or skin Remarks: No data available | | |
| damage/eye irritation Respiratory or skin Remarks: No data available | • | Species rabbit Poculty Mild avairation |
| Respiratory or skin Remarks: No data available | | Species, rabbit result, mild eye irritation |
| | | |
| sensitization | | Remarks: No data available |
| | sensitization | |

| Germ cell mutagenicity | Test Type: Chromosome aberration test in virto. Test Species: Chinese hamster ovary (CHO) Metabolic Activation: With and without metabolic activation. Method Mutagenicity (in vitro mammalian cytogenetic test) Result: Negative. Test Type: Sistrer chromatic exchange assay in mammalian cells. |
|------------------------|---|
| Germ cell mutagenicity | Animal testing did not show any mutagenic effects. |
| Assessment | |
| Carcinogenicity | Species: mouse, (male and female) Application Route: Oral Exposure time: 103 wk Dose: 0, 500 or 1000 mg/kg Frequency of Treatment: 5 days/week Method: Directive 67/548/EEC, Annex V, B.32. Result: did not display carcinogenic properties GLP: No data available, Carcinogenicity - Assessment: Animal testing did not show any carcinogenic effects. |
| Reproductive toxicity | Effects on fertility: Test Type: Two-generation study Species: rat, male and female Application Route: Inhalation Dose: 0, 25, 100 and 500 ppm Duration of Single Treatment: 6 h Frequency of Treatment: 7 days/week General Toxicity - Parent: NOAEC: > 500 ppm General Toxicity F1: NOAEC: > 500 ppm Early Embryonic Development: NOAEC: > 500 ppm Result: No reproductive effects. Effects on fetal development: Species: rat Application Route: Inhalation Dose: 0, 100, 500, 1000 or 2000 ppm Duration of Single Treatment: 14 d Frequency of Treatment: 6 hr/day General Toxicity Maternal: NOAEC: 500 ppm Teratogenicity: NOAEC: > 2,000 Developmental Toxicity: NOAEC: 100 ppm Result: No teratogenic effects., Developmental toxicity occurred at maternal toxicity dose levels Reproductive toxicity - Assessment: Animal testing did not show any effects on fertility. Damage to fetus not classifiable |
| STOT - single exposure | No data available. |
| STOT - repeated | Target Organs: Liver, Kidney, Central nervous system Assessment: May cause damage to |
| exposure | organs through prolonged or repeated exposure. |
| Repeated dose toxicity | Species: rat, male and female NOAEL: 250 mg/kg Application Route: Oral Exposure time: 103 wk Number of exposures: 5 d/wk Dose: 0, 250 or 500 mg/kg Assessment: The substance or mixture is classified as specific target organ toxicant, repeated exposure, category 2. |
| Aspiration Toxicity | May be fatal if swallowed and enters airways. |

12. ECOLOGICAL INFORMATION

| 2-Ethylhexanoic acid(14 | |
|--------------------------|--|
| Toxicity | No data available. |
| Persistence and | No data available. |
| degradability | |
| Bioaccumulative | No data available. |
| potential | |
| Mobility in soil | No data available. |
| Results of PBT and | PBT/vPvB assessment not available as chemical safety assessment not required/not |
| vPvB assessment | conducted |
| Other adverse effects | No data available. |
| Aliphatic Solvent(64742- | -47-8) |
| LC50 (Rainbow trout) | 2.9 mg/l - 96 h, Oncorhynchus mykiss (rainbow trout) |
| Toxicity to fish | |
| EC50 (Daphnia Magna) | 1.4 mg/l - 48 h, - Daphnia magna (Water flea), (OECD Test Guideline 202) |
| Tocicity to daphnia and | |
| other aquatic | |
| invertebrates | |
| Persistence and | No data available. |
| degradability | |
| Bioaccumulative | No data available. |
| potential | |
| Mobility in soil | No data available. |
| Results of PBT and | PBT/vPvB assessment not available as chemical safety assessment not required/not |
| vPvB assessment | conducted. |
| Other adverse effects | An environmental hazard cannot be excluded in the event of unprofessional handling or |
| | disposal. Toxic to aquatic life. No data available. |
| Barium Sulfate(7727-43 | |
| Toxicity - Aquatic | Not known. |
| toxicity | |
| Persistence and | The methods for determining biodegradability are not applicable to inorganic substances. |
| degradability | |
| Bioaccumulative | The product is practically insoluble in water and not biodegradable. |
| potential | |
| Mobility in soil | No information. |
| Results of PBT and | According to Annex XIII of regulation (EC) 1907/2006 a PBT and VPvB shall not be conducted |
| vPvB assessment | for inorganic substances. Barium sulfate is an inorganic substance, thus a PBT abs vPVb |
| | assessment is not required. |
| Other adverse effects | No information. |
| | |

| BENZENE(71-43-2) | | | |
|---|--|--|--|
| LC50 | 5.3 mg/l Exposure time: 96 h Species: Oncorhynchus mykiss (rainbow trout) flow-through test substance: yes Method: OECD Test Guideline 203 | | |
| EC50 | 10 mg/l Exposure time: 48 h Species: Daphnia magna (Water flea) static test substance: yes Method: OECD Test Guideline 202 | | |
| ErC50 | 100 mg/l Exposure time: 72 h Species: Pseudokirchneriella subcapitata (green algae) Test substance: yes Method: OECD Test Guideline 201 | | |
| Persistence and degradability | Biodegradability: This material is expected to be readily biodegradable. | | |
| Ecotoxicology Assessment | Acute aquatic toxicity Benzene : Toxic to aquatic life. Chronic aquatic toxicity Benzene : Harmful to aquatic life with long lasting effects. | | |
| Results of PBT assessment | This substance is not considered to be persistent, bioaccumulating nor toxic (PBT). This substance is not considered to be very persistent nor very bioaccumulating (vPvB). | | |
| Additional ecological information | Toxic to aquatic life. An environmental hazard cannot be excluded in the event of unprofessional handling or disposal. Toxic to aquatic life. | | |
| Butyl Alcohol(71-36-3) | unprofessional flatiuming of disposal. Toxic to aquatic me. | | |
| LC50 Pimephales promelas - toxicity to fish | 1,840 mg/l - 96 h, Pimephales promelas (fathead minnow) | | |
| EC50 Daphnia magna Toxicity to Daphnia and other aquatic invertebrates | 1,983 mg/l - 48 h Daphina magna (Water Flea) | | |
| Persistence and | No data available | | |
| degradability Bioaccumulative potential | Bioaccumulation Oncorhynchus mykiss (rainbow trout) - 24 h - 921 mg/l | | |
| Mobility in Soil | No data available | | |
| Result of PBT and vPvB | PBT/vPvB assessment not available as chemical safety assessment not required/not | | |
| assessment not required/not conducted | conducted | | |
| Other adverse effects | No data available | | |
| Carbon Black(1333-86-4 | | | |
| LC50 Brachydanio reio (zebrafish) | >1000 mg/l (96 h) OECD (Guideline 203) | | |
| EC50 Daphnia magna (waterflea) | >5600 mg/l (24 h) OECD (Guideline 202) | | |
| NOEC 50 (Scenedesmus | > 10,000 mg/L, OECD (Guideline 201) | | |
| subspicatus) EC50 (Scenedesmus | > 10,000 mg/L, OECD (Guideline 201) | | |
| subspicatus) Behavior in water | Activated sludge, EC0 (3 h) > 800 mg/L. DEV L3 (TTC test) | | |
| treatment plants | | | |
| Environmental fate | Carbon black is an inert solid, stable and insoluble in water or organic solvents. Its vapour pressure is negligible. Based on these properties it is expected that carbon black will not occur in air or water in relevant amounts. Also potential for distribution via water or air can be dismissed. The deposition in soil or sediments is therefore the most relevant compartment of fate in the environment. | | |
| Bioaccumulation Potential | Potential bioaccumulation is not expected because of the physicochemical properties of the substance | | |
| Ethylene glycol mono bu | Ethylene glycol mono butyl ether(111-76-2) | | |
| LC50 (fish) | 1,474 mg/l Pimephales promelas (Fathead minnow))Exposure time: 96 h Test Type: static test, Method: OECD Test Guideline 203 GLP: no | | |
| EC50 (Daphnia) | 1,800 mg/l(48 h; Daphnia magna (Water flea)): Exposure time: 48 h Test Type: static test Method: OECD Test Guideline 202 GLP: no | | |
| EC50 (Algae) | 911 mg/l End point: Biomass Exposure time: 72 h Test Type: static test Analytical monitoring: yes Method: OECD Test Guideline 201 GLP: no | | |
| Persistence and degradability | aerobic Inoculum: Activated sludge, domestic, adaption not specified, Result: Readily biodegradable. Biodegradation: 90.4 % Exposure time: 28 d Method: OECD Test Guideline 301B GLP: no | | |
| Bioaccumulative potential | Partition coefficient: n-octanol/water: log Pow: 0.83 | | |
| Mobility in soil | No data available | | |
| Other adverse effects Product | No data available Regulation: 40CFR Protection of Environment, Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class 1 Substances: | | |
| Glycol Ether PM(107-98- Toxicity | | | |
| 1 Oxidity | | | |

| Persistence and degradability | No data available. |
|--|--|
| Bioaccumulative potential | No data available. |
| Mobility in soil | No data available. |
| Results of PBT and | PBT/vPvB assessment not available as chemical safety assessment not required/not |
| vPvB assessment | conducted. |
| Other adverse effects | No data available. |
| Meta-Xylene(108-38-3) | |
| LC50 (Fish) | 11.23 mg/l - 96 h (OECD Test Guideline 203) |
| Toxicity to daphnia and | Remarks: No data available. |
| other aquatic invertebrates | |
| Toxicity to algae | Remarks: No data available |
| Persistence and | No data available. |
| degradability | |
| Bioaccumulative | Due to the distribution coefficient n-octanol/water, accumulation in organisms is not |
| potential | expected. |
| Mobility in soil | No data available. |
| Results of PBT and vPvB assessment | PBT/vPvB assessment not available as chemical safety assessment not required/not conducted. |
| Other adverse effects | An environmental hazard cannot be excluded in the event of unprofessional handling or |
| Janes daverse effects | disposal. Harmful to aquatic life with long lasting effects. |
| Methyl Ethyl Ketoxime(9 | 06-29-7) |
| LC50 - Oryzias latipes - | >100 mg/l, 96 h, - Oryzias latipes - (OECD Test Guideline 203) |
| Toxicity to fish | 100 mg// 40 h Doubling manage (W. L. (L.) (OFCD T. (.C.) L. () |
| EC50 - Daphnia magna - Toxicity to daphnia | >100 mg/l, 48 h, Daphnia magna (Water flea) - (OECD Test Guideline 202) |
| and other aquatic | |
| invertebrates | |
| EC50 - Scenedesmus | 11.6 mg/l, 72 h, Scenedesmus capricornutum (fresh water algae) - (OECD Test Guideline |
| capricornutum - | 201) |
| Toxicity to algae | |
| Persistence and | MEKO has been determined to be biodegradable. |
| degradability Bioaccumulative | Bioaccumulation Cyprinus carpio (Carp) - 42 d - 2 mg/l Bioconcentration factor (BCF): 0.5 - |
| potential | 0.6 (OECD Test Guideline 305C) |
| Mobility in soil | No data available. |
| Results of PBT and | PBT/vPvB assessment not available as chemical safety assessment not required/not |
| vPvB assessment | conducted |
| Other adverse effects Phenylethane(100-41-4) | No data available. |
| LC50 (Oncorhynchus | 4.2 mg/l Exposure time: 96 h Test Type: semi-static test |
| mykiss (rainbow | 1 4.2 mg/r Exposure time. 50 if rest Type. Semi static test |
| trout)) | |
| EC50 (Daphnia magna | 1.8 mg/l Exposure time: 48 h Test Type: static test |
| (Water flea)) | |
| EC50 | 5.4 mg/l Exposure time: 72 h Test Type: static test Analytical monitoring: yes Method: Static |
| (Pseudokirchneriella subcapitata) | GLP: yes |
| Toxicity to daphnia and | (Daphnia): 3.6 mg/l Toxicity to bacteria : GLP: Remarks: No data available Ecotoxicology |
| other aquatic | Assessment Chronic aquatic toxicity: Harmful to aquatic life with long lasting effects. |
| invertebrates (Chronic | |
| toxicity) | Diadaguadahilitu . Tagauluga, ashiyatad aludaa Caraantustian 22 may // Danultu D. 19 |
| Persistence and degradability | Biodegradability: Inoculum: activated sludge Concentration: 22 mg/l Result: Readily biodegradable. Biodegradation: 70 % Exposure time: 28 d GLP: yes |
| Bioaccumulative | Partition coefficient: noctanol/water : log Pow: 2.92 |
| potential | |
| Mobility in soil | No data available. |
| Other adverse effects | Results of PBT and vPvB assessment : This substance is not considered to be persistent, |
| | bioaccumulating nor toxic (PBT). This substance is not considered to be very persistent nor |
| Red Iron Oxide(1309-37 | very bioaccumulating (vPvB). |
| Toxicity | No Data Availble |
| Persistence and | No Data Available |
| Degradability | |
| Conclusion/Summary | No Data Available |
| Bioaccumulative | No Data Available |
| Potential | |

| Mobility in Soil | No Data Available |
|-------------------------|--|
| Mobility in Soil | No Data Available |
| Other Adverse Affects | No Data Available |
| Titanium Dioxide(13463 | |
| LC50 fish | Fathead minnow 96 h >1000 mg/l |
| Toluene(108-88-3) | |
| LC50 (Oncorhynchus | 5.5 mg/l Exposure time: 96 h Test Type: flow-through test |
| mykiss (rainbow | |
| trout)) | |
| EC50 (Ceriodaphnia | 3.78 mg/l Exposure time: 48 h Test Type: Renewal |
| | 3.76 High Exposure time. 46 if rest Type. Kenewai |
| dubia) | |
| EC50 (Chlorella | 134 mg/l Exposure time: 3 h Test Type: static test |
| vulgaris (Fresh water | |
| algae)) | |
| IC50 (Bacteria) | 84 mg/l Exposure time: 24 h, Test Type: Static Ecotoxicology Assessment Acute aquatic |
| | toxicity: Toxic to aquatic life. Chronic aquatic toxicity: Toxic to aquatic life with long lasting |
| | effects. |
| Persistence and | Biodegradability: Inoculum: Sewage Biodegradation: 100 % Remarks: Readily biodegradable |
| degradability | |
| Bioaccumulative | Partition coefficient: noctanol/water : log Pow: 2.73 |
| potential | . a. a.a Gottine in the carroy water . log 1 ow. 2.75 |
| Mobility in soil | No data available. |
| | |
| Other adverse effects | No data available. |
| Triethylamine(121-44-8) | |
| LC50 - Oryzias latipes- | 24 mg/l - 96 h, Oryzias latipes (Orange-red killifish) - (OECD Test Guideline 203) |
| Toxicity fo fish | |
| LC50 - Daphnia dubia - | 17 mg/l - 48 h, Daphnia dubia (water flea) |
| Toxicity to daphnia and | |
| other aquatic | |
| invertebrates | |
| EC50 - | 8 mg/l - 72 h, Pseudokirchneriella subcapitata (green algae) - (OECD Test Guideline 201) |
| Pseudokirchneriella | 0 mg, |
| subcapitata - Toxicity | |
| | |
| to algae NOEC - | 1.1 mg/l - 72 h, Pseudokirchneriella subcapitata (green algae) - (OECD Test Guideline 201) |
| | 1.1 mg/1 - 72 m, Pseudokii cimeriella subcapitata (green algae) - (OLCD Test Guideline 201) |
| Pseudokirchneriella | |
| subcapitata | |
| LC50 - Toxicity to | 95 mg/l. 17 h |
| bacteria | |
| Persistence and | Biodegradability aerobic - Exposure time 28 d Result: 80 % - Readily biodegradable (OECD |
| degradability | Test Guideline 301B) |
| Bioaccumulative | Bioaccumulation Cyprinus carpio (Carp) - 42 d Bioconcentration factor (BCF): < 0.5 (OECD |
| potential | Test Guideline 305C) Remarks: Does not bioaccumulate. |
| Mobility in soil | No data available. |
| Results of PBT and | PBT/vPvB assessment not available as chemical safety assessment not required/not |
| vPvB assessment | conducted. |
| Other adverse effects | An environmental hazard cannot be excluded in the event of unprofessional handling or |
| | disposal. Toxic to aquatic life. |
| VM&P Naphtha(64742-8 | |
| LL50 (Fish) | 8.2 mg/l Exposure time: 96 h Test Type: semi-static test Analytical monitoring: yes GLP: yes |
| EL50 (Daphnia magna | 4.5 mg/l Exposure time: 48 h Test Type: Immobilization Analytical monitoring: yes CET: Yes |
| (Water flea)) | substance: Naphtha GLP: yes |
| EL50 | 3.7 mg/l Exposure time: 96 h Test Type: static test Analytical monitoring: yes GLP: yes. |
| | |
| (Pseudokirchneriella | Ecotoxicology Assessment Acute aquatic toxicity: Harmful to aquatic organisms. |
| subcapitata (green | |
| algae)) | |
| Persistence and | Biodegradability: Concentration: 49.2 mg/l Result: Readily biodegradable. Biodegradation: |
| degradability | 77 % Testing period: 2 d Exposure time: 28 d GLP: yes |
| Bioaccumulative | Partition coefficient: noctanol/water: log POW: 2.13 - 4.85 (25 °C) |
| potential | |
| Mobility in soil | No data available. |
| Other adverse effects | No data available. |
| Xylene(1330-20-7) | |
| LC50 (Oncorhynchus | 2.6 mg/l Exposure time: 96 h Test substance: Information given is based on data obtained |
| mykiss (rainbow | from similar substances. Method: OECD Test Guideline 203 GLP: No data available |
| trout)) | 1.5.1. 5.11.1.di Substancesi Fredroat GEOD Test Guideline 205 GEL. No data avallable |
| | 1 mg/l Evnoquen timo. 24 h Tost Tuno. statis tost Tost substance. Information sixon in land |
| IC50 (Daphnia magna | 1 mg/l Exposure time: 24 h Test Type: static test Test substance: Information given is based |
| (Water flea)) | on data obtained from similar substances. Method: OECD Test Guideline 202 GLP |

| EC50 (Pseudokirchneriella subcapitata) | 4.36 mg/l End point: Growth rate Exposure time: 73 h Test Type: static test Analytical monitoring: yes |
|--|--|
| Persistence and degradability | Biodegradability: Inoculum: activated sludge Result: Readily biodegradable. Biodegradation: 72 % Exposure time: 20 d |
| Bioaccumulative potential | Partition coefficient: noctanol/water : log Pow: 2.77 - 3.15 |
| Mobility in soil | No data available. |

13. DISPOSAL CONSIDERATIONS

WASTE TREATMENT METHODS

GENERAL INFORMATION: No data available.

DISPOSAL METHOD: Recycle whenever possible or destroy by liquid incineration in accordance with applicable regulations. Contaminated absorbent should be incinerated or sent to an approved landfill in accordance with Local, State, and Federal Regulations.

14. TRANSPORT INFORMATION

*CHECK WITH YOUR CARRIER FOR ADDITIONAL RESTRICTIONS THAT MAY APPLY.

USDOT GROUND

DOT (DEPARTMENT OF TRANSPORTATION)

PROPER SHIPPING NAME (DOT): Not Regulated By D.O.T., 49 CFR

HAZARDS CLASS: Not Applicable UN/NA NUMBER: Not Applicable PACKING GROUP: Not Applicable

EMERGENCY RESPONSE GUIDE (ERG): Not Applicable

IATA (AIR)

DOT (INTERNATIONAL AIR TRANSPORTATION ASSOCIATION)

PROPER SHIPPING NAME: IATA, Not Applicable

HAZARDS CLASS: Not Applicable UN/NA NUMBER: Not Applicable PACKING GROUP: Not Applicable

EMERGENCY RESPONSE GUIDE (ERG): Not Applicable

IMDG (OCEAN)

PROPER SHIPPING NAME: IMDG, Not Applicable

HAZARDS CLASS: Not Applicable UN/NA NUMBER: Not Applicable PACKING GROUP: Not Applicable

EMERGENCY RESPONSE GUIDE (ERG): Not Applicable

MARINE POLLUTANT: No

SPECIAL PRECAUTIONS: P403 Store in a well-ventilated place. P235 Keep cool.

15. REGULATORY INFORMATION

US FEDERAL REGULATIONS

All ingredients in Section #3 are TSCA (Toxic Substance Control Act) listed.

OSHA HAZARDS: Flammable liquid, Moderate skin irritant, Moderate eye irritant, Carcinogen.

EPCRA - Emergency

CERCLA REPORTABLE QUANTITY

| This product contains: | Chemical CAS# |
|----------------------------------|---------------|
| Ethylene glycol mono butyl ether | 111-76-2 |
| VM&P Naphtha | 64742-89-8 |
| Xylene | 1330-20-7 |
| Phenylethane | 100-41-4 |
| Carbon Black | 1333-86-4 |

SARA 304 Extremely Hazardous Substances Reportable Quantity: This material does not contain any components with a section 304 EHS RQ.

SARA TITLE III (SUPERFUND AMENDMENTS AND REAUTHORIZATION ACT)

SARA 311/312 Hazards: Fire Hazard, Acute Health Hazard, Chronic Health Hazard

SARA 313:

| This product contains: | Chemical CAS# |
|----------------------------------|---------------|
| Titanium Dioxide | 13463-67-7 |
| Glycol Ether PM | 107-98-2 |
| Ethylene glycol mono butyl ether | 111-76-2 |
| Amorphous Silica | 7631-86-9 |

CLEAN AIR ACT:

| This product contains: | Chemical CAS# |
|------------------------|---------------|
| Triethylamine | 121-44-8 |
| Phenylethane | 100-41-4 |
| BENZENE | 71-43-2 |
| Toluene | 108-88-3 |
| Meta-Xylene | 108-38-3 |

INTERNATIONAL REGULATIONS

CLASSIFICATION ACCORDING TO REGULATION (EC) No. 1272/2008 (CLP):

Acute Tox. Oral Cat. 4; H302 Acute tox. Dermal Cat 4 H312 Skin Irrit, Cat. 2: H315 Eye Irrit. Cat. 2A; H319 Acute Tox. Inhal. Cat. 4 H332 Carc. Cat. 2; H351 STOT RE Cat. 2; H373

NATIONAL REGULATIONS

| This product contains: | Chemical CAS# |
|------------------------|---------------|
| ~Titanium Dioxide | 13463-67-7 |

IARC KEY

- ~ Indicates a chemical listed by IARC as a possible carcinogen.
- ^ Indicates a chemical listed by IARC as a carcinogen.

STATE REGULATIONS **CALIFORNIA PROPOSITION 65**

| This product contains: | Chemical CAS# |
|------------------------|---------------|
| *Aliphatic Solvent | 64742-47-8 |
| *Phenylethane | 100-41-4 |

PROPOSTION 65 KEY

* **WARNING** Cancer – <u>www P65Warnings.ca.gov</u>

WARNING Reproductive Harm – www P65Warnings.ca.gov

+ MARNING Cancer and Reproductive Harm – www P65Warnings.ca.gov

Massachusetts Right to Know

| This product contains | Chemical CAS# |
|----------------------------------|---------------|
| Glycol Ether PM | 107-98-2 |
| Ethylene glycol mono butyl ether | 111-76-2 |
| Silica Gel | 112926-00-8 |
| Triethylamine | 121-44-8 |
| Red Iron Oxide | 1309-37-1 |
| Xylene | 1330-20-7 |
| Aliphatic Solvent | 64742-47-8 |
| Phenylethane | 100-41-4 |
| Butyl Alcohol | 71-36-3 |
| Carbon Black | 1333-86-4 |
| Barium Sulfate | 7727-43-7 |
| BENZENE | 71-43-2 |

Pennsylvania Right to Know

| This product contains | Chemical CAS# |
|----------------------------------|---------------|
| Water | 7732-18-5 |
| Titanium Dioxide | 13463-67-7 |
| Glycol Ether PM | 107-98-2 |
| Ethylene glycol mono butyl ether | 111-76-2 |
| Amorphous Silica | 7631-86-9 |
| Aluminum Hydroxide | 21645-51-2 |
| Silica Gel | 112926-00-8 |
| Triethylamine | 121-44-8 |
| Red Iron Oxide | 1309-37-1 |
| Methyl Ethyl Ketoxime | 96-29-7 |
| Xylene | 1330-20-7 |
| Aliphatic Solvent | 64742-47-8 |
| Phenylethane | 100-41-4 |
| Butyl Alcohol | 71-36-3 |
| 1,10-Phenanthroline | 66-71-7 |
| Carbon Black | 1333-86-4 |
| 2-Ethylhexanoic acid | 149-57-5 |
| Barium Sulfate | 7727-43-7 |
| Toluene | 108-88-3 |

New Jersey Right to Know

| This product contains | Chemical CAS# |
|----------------------------------|---------------|
| Water | 7732-18-5 |
| Titanium Dioxide | 13463-67-7 |
| Glycol Ether PM | 107-98-2 |
| Ethylene glycol mono butyl ether | 111-76-2 |
| Amorphous Silica | 7631-86-9 |
| Aluminum Hydroxide | 21645-51-2 |
| Silica Gel | 112926-00-8 |
| Triethylamine | 121-44-8 |
| Red Iron Oxide | 1309-37-1 |
| Methyl Ethyl Ketoxime | 96-29-7 |

| Xylene | 1330-20-7 |
|----------------------|------------|
| Aliphatic Solvent | 64742-47-8 |
| Phenylethane | 100-41-4 |
| Butyl Alcohol | 71-36-3 |
| 1,10-Phenanthroline | 66-71-7 |
| Carbon Black | 1333-86-4 |
| 2-Ethylhexanoic acid | 149-57-5 |
| Barium Sulfate | 7727-43-7 |

16. OTHER INFORMATION

Other Product Information

% Volatile by Volume: 66.95 % Volatile by Weight: 54.19 % Solids by volume: 33.05 % Solids by Weight: 45.81 % Exempt by Volume: 49.52 % Exempt by Weight: 41.12


VOC CONTENT: Excluding Exempt VOC: 311

Including Exempt VOC: 157

HMIS RATING

| Health : | 1* |
|-----------------------|----|
| Flammability : | 1 |
| Reactivity: | 0 |
| Personal Protection : | Н |

NFPA CODES



MANUFACTURER DISCLAIMER: The information contained in this Safety Data Sheet is considered to be true and accurate. Cardinal Industrial Finishes makes no warranties, expressed or implied, as to the accuracy and adequacy of this information. This data is offered solely for the user's consideration, investigation and verification.